Document:

EX-10.20

 Exhibit 10.20 

THE SYMBOL “[REDACTED]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN 

EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE 

COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 

I-Mab Biopharma (Hangzhou) Co., Ltd. 

 
  

Equity Transfer and Investment Agreement 
  

 
 September 15,
2020 

 Table of Contents 

 

							
	 Article 1
	 	Definitions	  	 	4	 
			
	 Article 2
	 	Equity Transfer	  	 	7	 
			
	 Article 3
	 	Closing Conditions	  	 	9	 
			
	 Article 4
	 	Closing and Related Matters	  	 	12	 
			
	 Article 5
	 	Representations and Warranties	  	 	18	 
			
	 Article 6
	 	Transitional Period Covenants	  	 	26	 
			
	 Article 7
	 	Other Agreements and Covenants	  	 	28	 
			
	 Article 8
	 	Liability for Breach of Contract; Indemnification.	  	 	29	 
			
	 Article 9
	 	Effectiveness, Amendment and Termination of this Agreement	  	 	29	 
			
	 Article 10
	 	Miscellaneous	  	 	30	 
			
	 Schedule 1
	 	List of Pipelines and Related Intangible Assets	  			
			
	 Schedule 2
	 	Shareholding Structures of the Company	  			
			
	 Schedule 3
	 	Key Employees List	  			
			
	 Schedule 4
	 	Closing Certificate	  			
			
	 Schedule 5
	 	Shareholders Resolutions	  			
			
	 Schedule 6
	 	Shareholders Agreement	  			
			
	 Schedule 7
	 	Amended Articles of Association	  			
			
	 Schedule 8
	 	Personnel Transfer Plan	  			
			
	 Schedule 9
	 	Disclosure Schedules	  			

 EQUITY TRANSFER AND INVESTMENT AGREEMENT 

This EQUITY TRANSFER AND INVESTMENT AGREEMENT (this “Agreement”) is entered into in the PRC on Sep 15, 2020 (the “Signing
Date”) by and among the following parties: 
  

	1.	 I-Mab Biopharma (Hangzhou) Co., Ltd., a limited liability
company legally established and existing in accordance with the PRC laws, whose unified social credit code is 91330100MA2GNANB49 (the “Company”); 

 

	2.	 I-MAB BIOPHARMA HONG KONG LIMITED, a limited company legally
established and existing in accordance with the laws of the Hong Kong Special Administrative Region of the PRC, whose registration number is 2400410 (“I-Mab HK” or
“Warrantor”); 

  

	3.	 Hangzhou Fushi Investment Management Partnership (Limited Partnership)
(杭州赋实投资管理合伙企业(有限合伙)), a limited partnership legally established and existing in accordance with
the PRC laws, whose unified social credit code is 91330102MA2AYYBD4Q (“Fushi Capital”); 

  

	4.	 Shenzhen Tsingsong Shengrui Investment Partnership (Limited
Partnership)(深圳市青松晟睿投资合伙企业(有限合伙)), a limited partnership legally established and existing in
accordance with the PRC laws, whose unified social credit code is 91440300MA5FYAQD4R (“Tsingsong Shenzhen”); 

  

	5.	 Nanjing Tsingsong Healthcare Investment Partnership (Limited
Partnership)(南京清松医疗健康产业投资合伙企业(有限合伙)), a limited partnership legally
established and existing in accordance with the PRC laws, whose unified social credit code is 91320113MA21DH7W5M (“Tsingsong Nanjing”); 

  

	6.	 Hangzhou Heda Biotech Investment Partnership (Limited
Partnership)(杭州和达生物医药创业投资合伙企业(有限合伙)), a limited partnership legally
established and existing in accordance with the PRC laws, whose unified social credit code is 91330101MA2AXNXM21 (“Heda Investment”); 

  

	7.	 Xiamen Ronghui Derong Equity Investment Partnership (Limited Partnership)
(厦门融汇德润股权投资合伙企业(有限合伙)), a limited partnership legally established and existing in
accordance with the PRC laws, whose unified social credit code is 91350211MA34071K50 (“Ronghui Derong”); 

  

	8.	 Ningbo Yanyuan Yaoshang Chanrong Equity Investment Partnership (Limited
Partnership)(宁波燕园姚商产融股权投资合伙企业(有限合伙)), a limited partnership legally
established and existing in accordance with the PRC laws, whose unified social credit code is 91330281MA2H6M3084 (“Yanyuan Chanrong”); 

  

	9.	 Ningbo Yanchuang Yaoshang Yangming Investment Partnership (Limited
Partnership)(宁波燕创姚商阳明创业投资合伙企业(有限合伙)), a limited partnership legally
established and existing in accordance with the PRC laws, whose unified social credit code is 91330281MA2H6M3084 (“Yanchuang Yangming”); 

  
 1 

	10.	 Jiangsu Yanyuan Dongfang Investment Partnership (Limited
Partnership)(江苏燕园东方创业投资合伙企业(有限合伙)), a limited partnership legally established and
existing in accordance with the PRC laws, whose unified social credit code is 91320300MA1UQURD8F (“Yanyuan Dongfang”); 

  

	11.	 Ningbo Rongshun Yanyuan Investment Partnership (Limited
Partnership)(宁波荣舜燕园投资合伙企业(有限合伙)), a limited partnership legally established and existing in accordance
with the PRC laws, whose unified social credit code is 91330201MA2AJPJ617 (“Rongshun Yanyuan”); 

  

	12.	 Ningbo Yanyuan Innovation Investment Partnership (Limited
Partnership)(宁波燕园创新创业投资合伙企业(有限合伙)), a limited partnership legally established and existing
in accordance with the PRC laws, whose unified social credit code is 91330201340622519X (“Yanyuan Innovation”); 

  

	13.	 Zhuzhou Guochuang Junyao Investment Partnership (Limited
Partnership)(株洲市国创君垚投资合伙企业(有限合伙)), a limited partnership legally established and existing in
accordance with the PRC laws, whose unified social credit code is 91430200MA4RGB014A (“Guochuang Junyao”); 

  

	14.	 Ningbo Hanhai Qianyuan Equity Investment Partnership (Limited
Partnership)(宁波瀚海乾元股权投资基金合伙企业(有限合伙)), a limited partnership legally
established and existing in accordance with the PRC laws, whose unified social credit code is 91330212MA2GW05H0A (“Hanhai Qianyuan”); 

  

	15.	 Hangzhou Haibang Yigu Investment Partnership (Limited
Partnership)(杭州海邦羿谷创业投资合伙企业(有限合伙)), a limited partnership legally established and existing
in accordance with the PRC laws, whose unified social credit code is 91330101MA2B02RD4R (“Haibang Yigu”); 

  

	16.	 Jialiang Shan, a Chinese citizen, whose ID number is [REDACTED]; 

 

	17.	 Zhejiang Silu Industry Investment Fund Partnership (Limited
Partnership)(浙江丝路产业投资基金合伙企业(有限合伙)), a limited partnership legally established and existing
in accordance with the PRC laws, whose unified social credit code is 91330101MA28WHW02L (“Silu Fund”); 

  

	18.	 Viva Biotech (Shanghai) Ltd.
(维亚生物科技(上海)有限公司), a limited company legally established and existing in accordance with the PRC laws, whose unified
social credit code is 91310115677881436W (“Viva Biotech”); 

  

	19.	 Tianjin Huatian Enterprise Management Consultation Limited Partner (Limited Partner)
(天津华天企业管理咨询合伙企业(有限合伙)), a limited partnership legally established and existing in accordance with
the PRC laws, whose unified social credit code is 91120118MA0727C0X0 (“Huatian Enterprise Management”; together with Fushi Capital, Tsingson Shenzhen, Tsingsong Nanjing, Heda Investment, Ronghui Derong, Yanyuan Chanrong,
Yanhuang Yangming, Yanyuan Dongfang, Rongshun Yanyuan, Yanyuan Innovation, Guochuang Junyao, Hanhai Qianyuan, Haibing Yigu, Jialiang Shan, Silu Fund and Viva Biotch, collectively referred to as the “Investors”);

  
 2 

	20.	 Lili Qian, a Chinese citizen, whose ID number is [REDACTED]; 

 

	21.	 Zhengsong Zhang, a Chinese citizen, whose ID number is [REDACTED]; 

 

	22.	 Yunfei Zhang, a Chinese citizen, whose ID number is [REDACTED]; 

 

	23.	 Lihong Lou, a Chinese citizen, whose ID number is [REDACTED]; 

 

	24.	 Kai Zhou, a Chinese citizen, whose ID number is [REDACTED]; 

 

	25.	 Fang Yin, a Chinese citizen, whose ID number is [REDACTED] (together with Lili Qian, Zhengsong Zhang,
Yunfei Zhang, Lihong Lou and Kai Zhou, collectively referred to as the “Management”); 

  

	26.	 Hangzhou Yijing Biotech Partnership (Limited
Partnership)(杭州伊境生物科技合伙企业(有限合伙)), a limited partnership legally established and existing in accordance with the PRC
laws, whose unified social credit code is 91330100MA2HY0AEXX (“Management Holdco”); and 

  

	27.	 Hangzhou Lanjing Biotech Partnership (Limited
Partnership)(杭州阑境生物科技合伙企业(有限合伙)), a limited partnership legally established and existing in
accordance with the PRC laws, whose unified social credit code is 91330100MA2HY07T3Q (“ESOP Holdco”). 

 The above
parties are hereinafter collectively referred to as the “Parties”. When any party hereto is referred to as a “Party”, the other parties hereto will be referred to as the “Other Parties”. 

WHEREAS: 
  

	1.	 The Company is a limited liability company legally established and existing in accordance with PRC laws, which
was established on 26 June, 2019. The Company’s unified social credit code is 91330100MA2GNANB49, its current registered capital is US$30 million, and its business scope is: technology development, technology services, technology
consulting, and transfer of results: biotechnology, pharmaceutical technology (with respect to the above, except for the development and application of human stem cells, gene diagnosis and treatment technology); production: drugs; drugs,
pharmaceutical intermediates, Category I medical device wholesale and import and export business (except for those subject to special access control regulations stipulated by the state). 

 

	2.	 As of the Signing Date of this Agreement, I-Mab HK holds 100% of the
equity in the Company, represented by the Company’s registered capital of US$30 million, of which the paid-in registered capital is US$0. I-Mab HK is a wholly
owned Subsidiary of I-Mab天境生物 (NASDAQ: IMAB; hereinafter referred to as “I-Mab”).
I-Mab and its Subsidiaries are collectively referred to as the “Group”. 

  

	3.	 The Management Holdco is a limited partnership jointly established by the Management, which is used to hold
restricted equity of the Company issued to the Management. The Parties agree that the Management Holdco will acquire 10% of the equity of the Company from I-Mab HK for a total price of US$0, which equity is
represented by the Company’s unpaid registered capital of US$3 million, and that after acquiring such equity, it will pay RMB equivalent to US$3 million to the Company in accordance with terms of this Agreement to fulfil its capital
contribution obligations to the Company. Such capital contribution of RMB equivalent to US$3 million will be fully booked to the Company’s registration capital. 

  
 3 

	4.	 The Parties agree that the ESOP Holdco will acquire 5% of the equity of the Company from I-Mab HK for a total price of US$0, which equity is represented by the Company’s unpaid registered capital of US$1.5 million. All of such equity will be used to implement the Company’s equity
incentive plan. 

  

	5.	 The Parties agree that the Investors, in accordance with the terms of this Agreement, will acquire a total of
40% of the equity of the Company from I-Mab HK for a total price of US$0, which equity is represented by the Company’s unpaid registered capital of US$12 million, and after acquiring such equity of
the Company, it will pay RMB equivalent to US$120 million (with respect to each Investor, calculated according to the USD to RMB central parity rate announced by the People’s Bank of China on the day of payment) (collectively referred to
as the “Investors Investment Amount” to the Company in accordance with the terms of this Agreement to fulfil its capital contribution obligations to the Company. Among the capital contribution of RMB equivalent to
US$120 million, RMB equivalent to US$12 million will be booked to the Company’s registration capital, and the remaining RMB equivalent to US$108 million will be booked to the Company’s capital reserve. 

 

	6.	 After completion of the foregoing equity transfer, I-Mab HK will hold
the remaining 45% of the equity in the Company, which equity will be represented by the Company’s registered capital of US$13.5 million. I-Mab HK agrees to transfer to the Company the Pipeline
Intangible Assets with a total valuation of US$105 million and pay to the Company US$30 million in cash, to fulfil its capital contribution obligations to the Company, of which US$13.5 million cash will be booked to the Company’s
registered capital, and the Pipelines Intangible Assets valued at US$105 million and the remaining US$16.5 million cash will be booked to the Company’s capital reserve. 

 

	7.	 On the Signing Date of this Agreement, the Parties will also sign a Shareholder Agreement (the
“Shareholder Agreement”) to further provide for the rights and obligations of the shareholders of the Company after the Closing Date. 

THEREFORE, the Parties have entered into the following agreement through negotiation: 

Article 1 Definitions 
  

	1.1	 Definitions The following terms shall have the following meanings when used in this
Agreement: 

  

			
	 Affiliate
	  	With respect to a Party, refers to any enterprise that controls or is controlled by such Party, or is under common control by the same entity with such Party. “Control” means directly or indirectly owning more than
fifty percent (50%) of equity, voting rights, or directly or indirectly owning more than fifty percent (50%) of any other equivalent assets of the enterprise, or other power or right that can independently determine the management of the enterprise.
“Entities” may include but are not limited to individuals, partnerships, companies and other legal entities.

  
 4 

			
	 Target Pipelines
	  	Refer to the pipelines listed in Schedule 1 to this Agreement; the “Intangible Assets” of Pipelines refer to the ownership and/or the intellectual property rights related to the pipeline listed in
Schedule 1 of this Agreement, in which the ownership and/or licensing rights of the pipeline related intellectual property rights are proposed to be contributed by I-Mab HK to the company under this
agreement. Respective names of the six pipelines are listed in Schedule 1 of this Agreement; the six pipelines are collectively referred to as the “Target Pipelines”.
		
	 Senior Officers
	  	Refer to general manager, deputy general manager, financial controller and other VP or above level officers.
		
	 Working Day
	  	Refers to any day except Saturdays, Sundays or Chinese legal holidays.
		
	 Qualified IPO
	  	The public offering of the Company’s shares on the China Stock Exchange’s Science and Technology Board, Main Board, Small and Medium-Sized Enterprise Board, Growth Enterprise Board,
or Hong Kong Stock Exchange, U.S. Stock Exchange, or other stock exchanges approved by the Shareholders of the Company in accordance with provisions of the Shareholders Agreement.
		
	 Transaction Documents
	  	Refer to this Agreement, the Shareholders Agreement, the Amended and Restated Articles of Association of the Company in form and substance attached hereto as Schedule 7 (referred to as the “Amended Articles of
Association”), and any other agreement or document in connection with the transactions contemplated hereunder which is entered into pursuant to any of the foregoing documents.
		
	 Person
	  	Refers to any natural person, legal person, partnership, limited liability company, company limited by shares, association, trust, unincorporated organisation, or any other legal entity of any nature established in accordance with
any Applicable Law, or any Government Agency.
		
	 MOFCOM
	  	Refers to the Ministry of Commerce of China and its counterparts at all levels that exercise similar powers.
		
	 Market Regulation Bureau
	  	Refers to the PRC’s State Administration for Market Regulation and its local counterparts that exercise similar powers at all levels.

  
 5 

			
	 Applicable Law
	  	With respect to any Person, refers to any public, valid and applicable treaties, laws, administrative regulations, local regulations, rules, decisions, orders, judicial interpretations, judgments, rulings, arbitration awards or
other normative documents that is applicable to that Person or binding on that Person or any of its assets.
		
	 Subsidiary
	  	With respect to any Person, refers to any legal person, partnership, limited liability company, company limited by shares, association, trust, or other entity in which the Person (alone or through or in collaboration with any other
Person) directly or indirectly owns securities or other interests in it, so that the Person generally has more than fifty percent (50%) of the voting rights in the election of the board of directors or other similar decision-making bodies, or in
which the Person is given the right to control by other means.
		
	 Intellectual Property
	  	Refers to patents, trademarks, service marks, registered designs, domain names, utility models, copyrights, inventions, confidential information, trade secrets, proprietary production processes and equipment, brand names, database
rights, trade names, or a right similar to any of the above, and the interest of any of the above (whether registered or unregistered, and including the application for the authorisation of the above items and the right to apply for any of the above
items anywhere in the world).
		
	 Material Adverse Change
	  	Refers to any material adverse impact or change that has caused a significant adverse effect on the Company’s Target Pipelines, business, management, financial condition, Intellectual Property, debt, Key Employees, governmental
approval, qualifications or expected future development (but in each case does not include any such material adverse impact or change that has been remedied or corrected); in case the Company incurs or is reasonable expected to incur a loss of
RMB5 million or more, it shall be deemed as a Material Adverse Change.
		
	 Government Agency
	  	Refers to any government or its affiliates with jurisdiction, any department or agency of any government or its affiliates, any legislative body, court or arbitral tribunal, and any stock exchange regulatory agency.
		
	 PRC
	  	Refers to the People’s Republic of China. For the purpose of this Agreement, it does not include the Hong Kong Special Administrative Region, Macau Special Administrative Region and
Taiwan.

  
 6 

			
	 Greater China
	  	Refers to the People’s Republic of China. For the purposes of this Agreement, it includes the Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan.
		
	 Force Majeure Event
	  	Refers to any objective event or circumstance that is unforeseeable, inevitable and unavoidable, including without limitation earthquake, typhoon, flood, fire or other natural disasters, strike, pandemic (including COVID-19), riot, war. For the avoidance of doubt, any change of laws, regulations, policies, government orders of any national, regional or local Government Agency that is unforeseeable on the Signing Date hereof
shall be deemed as Force Majeure.

 Article 2 Equity Transfer 
  

	2.1	 On the Signing Date of this Agreement, the Company’s registered capital is US$30 million, all
of which is subscribed by I-Mab HK, and the paid-in registered capital is US$0. After completion of the transaction contemplated hereunder, the registered capital of the
Company will remain to be US$30 million, among which the amount of registered capital respectively subscribed by the shareholders of the Company and their respective shareholding percentage in the Company are reflected in Schedule
2. 

  

	2.2	 Fushi Capital agrees to, on the Closing Date (as defined below), acquire 8.33% of the equity of the
Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$2.5 million
(“Fushi Capital Target Equity”). 

  

	2.3	 Tsingsong Shenzhen agrees to, on the Closing Date, acquire 5.52% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$1.655 million (“Tsingsong
Shenzhen Target Equity”). 

  

	2.4	 Tsingsong Nanjing agrees to, on the Closing Date, acquire 2.82% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$0.845 million (“Tsingsong
Nanjing Target Equity”). 

  

	2.5	 Heda Investment agrees to, on the Closing Date, acquire 6.67% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$2 million (“Haibang Fenghua
Target Equity”). 

  

	2.6	 Ronghui Derong agrees to, on the Closing Date, acquire 3.33% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$1 million (“Ronghui Derong
Target Equity”). 

  
 7 

	2.7	 Yanyuan Chanrong agrees to, on the Closing Date, acquire 0.67% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$0.2 million (“Yanyuan Chanrong
Target Equity”). 

  

	2.8	 Yanchuang Yangming agrees to, on the Closing Date, acquire 1.07% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$0.32 million (“Yanchuang
Yangming Target Equity”). 

  

	2.9	 Yanyuan Dongfang agrees to, on the Closing Date, acquire 0.93% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$0.28 million (“Yanyuan Dongfang
Target Equity”). 

  

	2.10	 Rongshun Yanyuan agrees to, on the Closing Date, acquire 0.83% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$0.25 million (“Rongshun Yanyuan
Target Equity”). 

  

	2.11	 Yanyuan Innovation agrees to, on the Closing Date, acquire 0.83% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$0.25 million (“Yanyuan
Innovation Target Equity”). 

  

	2.12	 Guochuang Junyao agrees to, on the Closing Date, acquire 2.33% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$0.7 million (“Guochuang Junyao
Target Equity”). 

  

	2.13	 Hanhai Qianyuan agrees to, on the Closing Date, acquire 2.33% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$0.7 million (“Hanhai Qianyuan
Target Equity”). 

  

	2.14	 Haibang Yigu agrees to, on the Closing Date, acquire 1% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$0.3 million (“Haibang Yigu
Target Equity”). 

  

	2.15	 Jialiang Shan agrees to, on the Closing Date, acquire 1% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$0.3 million (“Jialiang Shan
Target Equity”). 

  

	2.16	 Silu Fund agrees to, on the Closing Date, acquire 1% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$0.3 million (“Silu Fund Target
Equity”). 

  
 8 

	2.17	 Viva Biotech agrees to, on the Closing Date, acquire 1% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$0.3 million (“Viva Biotech
Target Equity”). 

  

	2.18	 Huatian Enterprise Management agrees to, on the Closing Date, acquire 0.67% of the equity of the Company
from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$0.2 million (“Huatian
Enterprise Management Target Equity”). 

  

	2.19	 The Management Holdco agrees to, on the Closing Date, acquire 10% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which equity is represented by the Company’s unpaid registered capital of US$3 million (“Management Target
Equity”), and each member of the Management agrees to procure the Management Holdco to acquire such equity. 

  

	2.20	 The ESOP Holdco agrees to, on the Closing Date, acquire 5% of the equity of the Company from I-Mab HK for the price of US$0 according to the terms and conditions stipulated herein, which is represented by the Company’s unpaid registered capital of US$1.5 million (“ESOP Target
Equity”, together with Management Target Equity, Fushi Capital Target Equity, Tsingson Shenzhen Target Equity, Tsingsong Nanjing Target Equity, Heda Investment Target Equity, Ronghui Derong Target Equity, Yanyuan Chanrong Target Equity,
Yanhuang Yangming Target Equity, Yanyuan Dongfang Target Equity, Rongshun Yanyuan Target Equity, Yanyuan Innovation Target Equity, Guochuang Junyao Target Equity, Hanhai Qianyuan Target Equity, Haibing Yigu Target Equity, Jialiang Shan Target
Equity, Silu Fund Target Equity and Viva Biotch Target Equity, collectively referred to as the “Target Equity”). 

  

	2.21	 I-Mab HK agrees to transfer the Target Equity to the
above-mentioned Parties in accordance with the above mentioned terms and conditions (collectively referred to as “Equity Transfer”). The Equity Transfer shall take effect on the Closing Date. After completion of the above-mentioned
Equity Transfer, I-Mab HK will hold the remaining 45% of the equity in the Company, represented by the Company’s registered capital of US$13.5 million. 

Article 3 Closing Conditions 
  

	3.1	 Conditions Precedent. Each Investor’s obligation to complete the equity transfer
related to it and pay its respective portion of the Investors Investment Amount and I-Mab HK’s obligation to transfer corresponding Target Equity of the Company to the Investors pursuant to Article 2
(collectively, the “Closing”) shall be subject to the following conditions (each of which is referred to as a “Condition Precedent”) being satisfied or waived in writing by the Investors of whom the subscribed
capital contribution exceeds two thirds of the total subscribed capital contribution of all Investors, and who shall include the Investors who are entitled to appoint Investor Directors (as defined in the Shareholders Agreement) pursuant to the
Shareholders Agreement (collectively, the “Majority Investors”), on or prior to the Closing Date: 

  

	 	(1)	 The Investors have completed the business, legal, and financial due diligence on the Company;

  
 9 

	 	(2)	 The representations and warranties made by the Company herein are true, accurate, complete and not misleading
in all material respects on the Signing Date and the Closing Date, there is no Material Adverse Change in the Company, and the Company shall have delivered a Closing Certificate to the Investor in the form and substance as attached hereto as
Schedule 4; 

  

	 	(3)	 Except the relevant Market Regulation Bureau Registration (as defined below), tax registration, MOFCOM foreign
invested companies information reporting and change of foreign exchange registration, the Company has obtained and completed all necessary authorisations, consents and approvals required for the execution, delivery and performance of the Transaction
Documents and the transactions contemplated thereunder (including but not limited to the Shareholders Resolutions of the Company’s Shareholders in the form and substance as attached hereto as Schedule 5; and the competent
authority of I-Mab shall have duly approved the transactions contemplated hereunder, including, it shall have duly approved transfer of all Intangible Assets of the Licensed Pipelines to the Company);

  

	 	(4)	 This Agreement has been duly executed and delivered by the Parties, has become effective, and remains fully
effective on the Closing Date; 

  

	 	(5)	 The Shareholder Agreement in the form and substance attached hereto as Schedule 6 has been
duly executed and delivered by the Parties, and shall take effect on and from the Closing Date; 

  

	 	(6)	 The Amended Articles of Association in the form and substance attached hereto as Schedule 7 has
been duly executed and delivered by I-Mab HK, the Investors, the Management Holdco and the ESOP Holdco, and shall take effect on and from the Closing Date; 

 

	 	(7)	 The Parties shall have duly executed and delivered other Transaction Documents (if any) which, according to
terms thereof, shall be executed on or prior to the Closing Date; 

  

	 	(8)	 All the rights and interests of the of Target Pipelines listed in the first part of Schedule 1
(the “Licensed Pipelines”) have been transferred to the Company by I-Mab HK, and there is no pledge or other incumbrance on such rights and interests; more specifically, (i) the rights
and interests of Pipeline TJ301 shall have been exclusively sublicensed by I-Mab to I-Mab HK, and then exclusively sublicensed by
I-Mab HK to the Company; (ii) with respect to the rights and interests of Pipeline TJL1A3, I-Mab Biopharma (Shanghai) Co., Ltd. (“I-Mab Shanghai”) shall have assigned all of its rights and obligations under the agreement related to Pipeline TJL1A3 (the “TJL1A3 Agreement”) to
I-Mab HK, and then I-Mab HK shall have assigned all of its rights and obligations under the TJL1A3 Agreement to the Company; and (iii) with respect to the
Intangible Assets of Pipeline TJ102, I-Mab Bio-Tech (Tianjin) Co., Ltd. and I-Mab Shanghai shall have respectively assigned all
of their rights and obligations under the agreement related to TJ102 (the “TJ102 Agreement”) to I-Mab HK, and then I-Mab HK shall have assigned all of
its rights and obligations under the TJ102 Agreement to the Company; notification and approval procedures (if applicable) for the foregoing transfer shall have been duly performed; 

  
 10 

	 	(9)	 For the Intangible Assets of Target Pipelines listed in the second part of Schedule 1 (the
“Independently Developed Pipelines”), I-Mab HK shall have signed a binding agreement with the Company to the satisfaction of the Investors, stipulating that such Target Pipelines Intangible
Assets will be transferred to the Company after the Closing Date within a limited period of time (including without limitation, to register relevant Intellectual Property of the Independently Developed Pipelines under the Company’s name); more
specifically, such agreement shall stipulate that: (i) all patents and patent applications of TJA3, TJM2 and TJT6 in the Greater China, the United States, the European Union, Japan, the Republic of Korea, Australia and Canada (collectively, the
“Tier One Countries”) shall be transferred to the Company within twelve (12) months of the Closing Date, provided that the Parties acknowledge that completion time of the transfer of such patents and patent applications may be
impacted by COVID-19 and other factors out of I-Mab HK and the Company’s control, and that if the transfer of any or all of such patents and patent applications
cannot be completed within the aforesaid period due to impact of COVID-19 or other Force Majeure Event, then the aforesaid period shall be reasonably extended, I-Mab HK
will promptly notify the Investors, and I-Mab HK and the Majority Investors shall negotiate in good faith on extension of the aforesaid period; and (ii) with respect to patents and patent applications of
TJA3, TJM2 and TJT6 in the countries and regions other than the Tier One Countries, I-Mab HK shall, within twelve (12) months of the Closing Date, submit applications to the patent authorities of these
countries and regions for transfer of such patents and patent applications to the Company, and shall complete the procedures for transfer of such patents and patent applications as soon as practicable; provided that if any or all of the applications
for transfer of such patents and patent applications cannot be submitted within the aforesaid period due to impact of COVID-19 or other Force Majeure Event, then the aforesaid period shall be reasonably
extended, I-Mab HK will promptly notify the Investors, and I-Mab HK and the Majority Investors shall negotiate in good faith on extension of the aforesaid period.

  

	 	(10)	 The Company’s key employees (list of whom is attached to as Schedule 3) (the “Key
Employees”) have signed labour contracts, non-compete and intellectual property assignment agreements with the Company. 

 

	3.2	 Long-Stop Date. All Parties shall exert their best efforts to ensure that all Conditions
Precedent be satisfied no later than 30 September, 2020. If any of the Conditions Precedent is not met within such time limit and is not waived by the Majority Investors in writing, any Party has the right to terminate this Agreement by giving a
written notice to the Other Party. The termination of this Agreement shall be effective on and from the date of such written notice of termination. Notwithstanding the foregoing, the Party who bears the main responsibility or fault to which the
failure of satisfaction of any Condition Precedent within the above-mentioned deadline is attributable shall not have the right to terminate this Agreement in accordance with the provisions of this Article 3.2. At the Closing, if any of the
Conditions Precedent are waived in writing by the Majority Investors, unless expressly and permanently waived by all Investors, such Conditions Precedent shall automatically become post-Closing obligations under Article 4.3 of this Agreement, and
such obligations shall be fulfilled within the time limit otherwise agreed in writing by the Investors. 

  
 11 

 Article 4 Closing and Related Matters 

 

	4.1	 Time of Closing. Closing shall occur on the date of fulfilment of all the Conditions
Precedent listed in Article 3.1 of this Agreement (except for those Conditions Precedent that, according to their nature, must be achieved on the Closing Date) or waiver of the same by the Majority Investors in writing (the “Closing
Date”). 

  

	4.2	 Closing. The Investors shall remit their respective Investors Investment Amount to the
Company’s designated bank account to be provided by the Company at least two (2) Working Days prior to the Closing Date by wire transfer within ten (10) Working Days after the Closing Date or at the time otherwise agreed by the
Parties. The amount of Investors Investment Amount payable by each Investor shall be as follows: 

  

	 	(1)	 Fushi Capital shall pay RMB equivalent to US$25,000,000.00 (calculated according to the USD to RMB central
parity rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB equivalent to
US$2,500,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$22,500,000.00 shall be booked to the Company’s capital reserve as a premium. 

 

	 	(2)	 Tsingsong Shenzhen shall pay RMB equivalent to US$16,550,000.00 (calculated according to the USD to RMB central
parity rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB equivalent to
US$1,655,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$14,895,000.00 shall be booked to the Company’s capital reserve as a premium. 

 

	 	(3)	 Tsingsong Nanjing shall pay RMB equivalent to US$8,450,000.00 (calculated according to the USD to RMB central
parity rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB equivalent to
US$845,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$7,605,000.00 shall be booked to the Company’s capital reserve as a premium. 

 

	 	(4)	 Heda Investment shall pay RMB equivalent to US$20,000,000.00 (calculated according to the USD to RMB central
parity rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB equivalent to
US$2,000,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$18,000,000.00 shall be booked to the Company’s capital reserve as a premium. 

  
 12 

	 	(5)	 Ronghui Derong shall pay RMB equivalent to US$10,000,000.00 (calculated according to the USD to RMB central
parity rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB equivalent to
US$1,000,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$9,000,000.00 shall be booked to the Company’s capital reserve as a premium. 

 

	 	(6)	 Yanyuan Chanrong shall pay RMB equivalent to US$2,000,000.00 (calculated according to the USD to RMB central
parity rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB equivalent to
US$200,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$1,800,000.00 shall be booked to the Company’s capital reserve as a premium. 

 

	 	(7)	 Yanchuang Yangming shall pay RMB equivalent to US$3,200,000.00 (calculated according to the USD to RMB central
parity rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB equivalent to
US$320,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$2,880,000.00 shall be booked to the Company’s capital reserve as a premium. 

 

	 	(8)	 Yanyuan Dongfang shall pay RMB equivalent to US$2,800,000.00 (calculated according to the USD to RMB central
parity rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB equivalent to
US$280,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$2,520,000.00 shall be booked to the Company’s capital reserve as a premium. 

 

	 	(9)	 Rongshun Yanyuan shall pay RMB equivalent to US$2,500,000.00 (calculated according to the USD to RMB central
parity rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB equivalent to
US$250,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$2,250,000.00 shall be booked to the Company’s capital reserve as a premium. 

 

	 	(10)	 Yanyuan Innovation shall pay RMB equivalent to US$2,500,000.00 (calculated according to the USD to RMB central
parity rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB equivalent to
US$250,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$2,250,000.00 shall be booked to the Company’s capital reserve as a premium. 

  
 13 

	 	(11)	 Guochuang Innovation shall pay RMB equivalent to US$7,000,000.00 (calculated according to the USD to RMB
central parity rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB
equivalent to US$700,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$6,300,000.00 shall be booked to the Company’s capital reserve as a premium. 

 

	 	(12)	 Hanhai Qianyuan shall pay RMB equivalent to US$7,000,000.00 (calculated according to the USD to RMB central
parity rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB equivalent to
US$700,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$6,300,000.00 shall be booked to the Company’s capital reserve as a premium. 

 

	 	(13)	 Haibang Yigu shall pay RMB equivalent to US$3,000,000.00 (calculated according to the USD to RMB central parity
rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB equivalent to
US$300,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$2,700,000.00 shall be booked to the Company’s capital reserve as a premium. 

 

	 	(14)	 Jialiang Shan shall pay RMB equivalent to US$3,000,000.00 (calculated according to the USD to RMB central
parity rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB equivalent to
US$300,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$2,700,000.00 shall be booked to the Company’s capital reserve as a premium. 

 

	 	(15)	 Silu Fund shall pay RMB equivalent to US$3,000,000.00 (calculated according to the USD to RMB central parity
rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB equivalent to
US$300,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$2,700,000.00 shall be booked to the Company’s capital reserve as a premium. 

 

	 	(16)	 Viva Biotech shall pay RMB equivalent to US$2,000,000.00 (calculated according to the USD to RMB central parity
rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB equivalent to
US$200,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$1,800,000.00 shall be booked to the Company’s capital reserve as a premium. 

  
 14 

	 	(17)	 Huatian Enterprise Management shall pay RMB equivalent to US$2,000,000.00 (calculated according to the USD to
RMB central parity rate announced by the People’s Bank of China on the day of payment) to the Company, so as to fulfil its capital contribution obligations in connection with the Target Equity acquired by it. Among such investment amount, RMB
equivalent to US$200,000.00 shall be booked to the Company’s registered capital, and the remaining RMB equivalent to US$1,800,000.00 shall be booked to the Company’s capital reserve as a premium. 

I-Mab HK shall transfer the Intangible Assets of Target Pipelines listed in part 2 of Schedule
1 to the Company after the Closing Date within the timelines set forth in this Agreement and in the binding agreement between I-Mab and the Company, and shall pay the Company US$30 million in cash
on the Closing Date, so as to fulfil its capital contribution obligation in connection with the equity held by it in the Company after the Equity Transfer. The Parties agree that the total value of the Intangible Assets of all Target Pipelines to be
contributed by I-Mab HK to the Company shall be US$105 million. Among the above capital contributions of I-Mab HK, US$13.5 million in cash shall be booked to
the Company’s registered capital, and the remaining US$16.5 million in cash and the Intangible Assets of Target Pipelines valued at US$105 million shall be booked to the Company’s capital reserve. For the avoidance of doubt,
notwithstanding anything to the contrary in the Transaction Documents, the Equity Transfer contemplated in these transactions (if take effect) shall be deemed as taking effect on the Closing Date before any capital contribution by I-Mab HK to the Company. 
 The Management Holdco shall pay RMB equivalent to US$3 million (calculated
according to the USD to RMB central parity rate announced by the People’s Bank of China on the day of payment) to the Company in accordance with the provisions of Article 4.3(8) of this Agreement, so as to fulfil its capital contribution
obligation in connection with the Target Equity acquired by it. 
  

	4.3	 Post-Closing Covenants 

The Company, I-Mab HK, the Management and the Management Holdco hereby represent and covenant to the
Investors as follows: 
  

	 	(1)	 The Company shall, within one (1) month after the Closing, complete the registration of changes with the
Market Regulation Bureau (including the registration of Equity Transfer, shareholders change and shareholding percentage change, as well as filing for the Amended Articles of Association and the Company’s new Board of Directors, collectively
referred to as the “Market Regulation Bureau Registration”) for the transactions contemplated hereunder, obtain an updated business licence, and complete the necessary tax registration, MOFCOM foreign invested companies information
reporting, change of foreign exchange registration, and other registrations or filings required by Applicable Laws of the PRC. 

  
 15 

	 	(2)	 The Company and I-Mab HK covenant to complete the transfer of
Intangible Assets of the Independently Developed Pipelines from I-Mab HK to the Company as soon as practicable after the Closing Date in accordance with the provisions of this Agreement and relevant agreement
of the Independently Developed Pipelines, and shall cause the Group to, prior to such transfer, exert all efforts to maintain such Intangible Assets and avoid transferring any Intangible Assets or Ancillary Assets in connection with the
Independently Developed Pipelines to any third party other than the Company or creating any incumbrances on such assets. As of the Closing Date, the Group owns the complete and valid title of the Intellectual Property of the Independently Developed
Pipelines that are required to be transferred to the Company pursuant to this Agreement and agreement related to such Independently Developed Pipelines, and, to the knowledge of the Company, I-Mab HK and the
Management, no disputes exist in connection with ownership of such Intellectual Property; such Intellectual Property is reasonably expected to adequately meet the Company’s need to operate the Independently Developed Pipelines in a normal way,
with no incumbrances existing on such Intellectual Property. To the knowledge of the Company, I-Mab HK and the Management, as of the Closing Date, there exist no Intellectual Property related litigation,
opposition, appeal, interference, invalidation or cancellation procedures in connection with Intangible Assets of the Independently Developed Pipelines; and as of the Closing Date, the Group has not received any allegation, complaint, claims, demand
or notice on any infringement, improper use or violation in connection with such Intellectual Property. The Company shall validly obtain all approval, permit, license, certificate, consent or other approval documents of the Government Agencies that
are necessary for its operation of the Independently Developed Pipelines. 

  

	 	(3)	 I-Mab HK shall, as soon as practicable after the Closing, obtain an appraisal report on Intangible Assets of
the Target Pipelines issued by a qualified appraiser, and shall guarantee that the total valuation of Intangible Assets of the Target Pipelines in the appraisal report be not lower than US$105 million. If the total valuation of Intangible
Assets of the Target Pipelines in the appraisal report is lower than US$105 million, I-Mab HK shall make up for the deficiency in full by making additional cash contribution to the Company.

  

	 	(4)	 With respect to clinical trials of Pipeline TJ301, I-Mab HK and the
Company shall use reasonable efforts to obtain renewed approval from the Human Generic Resource Office as soon as practicable within two (2) months of the Closing Date. However, the Parties understand that the time of receiving such renewed
approval may be impacted by COVID-19, efficiency of the regulatory authority in its approval process, and other factors out of I-Mab HK and the Company’s control,
and that if the renewed approval cannot be obtained within two (2) months of the Closing Date, unless caused by I-Mab HK or the Company’s fault, the aforesaid time limit shall be reasonably extended,
the Company shall promptly notify the Investors, and the Company and the Majority Investors shall negotiate in good faith on extension of the aforesaid time limit. 

 

	 	(5)	 With respect to the joint patent applications of the Group and ABL Bio under Pipeline TJL1A3, the Group shall
transfer the relevant patent application rights to the Company and complete the corresponding Intellectual Property registration within twelve (12) months of the Closing Date; with respect to any intangible assets (if any) that are licensed by
the Group to ABL Bio under the TJL1A3 Agreement, the Group shall transfer such intangible assets to the Company and have the Company to license the same to ABL Bio. 

  
 16 

	 	(6)	 Subject to the Company having met objective conditions for receipt, all ancillary assets related to the Target
Pipelines and necessary for implementation and operation of the Target Pipelines, such as registration materials, samples, cell line and cell bank, technical platform, technical documents, etc. of the Target Pipelines (the “Ancillary
Assets”), shall be transferred to the Company prior to June 30, 2021, and all team handover, technology handover and technology matching in connection with the Intangible Assets and Ancillary Assets of the Target Pipelines shall be
completed prior to June 30, 2021, so as to ensure normal operation of the Target Pipelines in the Company. In the event of failure to transfer any part of the Ancillary Assets prior to June 30, 2021 as a result of any objective reasons
(e.g., the Company does not meet conditions for storage), such part of the Ancillary Assets shall be transferred to the Company as soon as practicable, and in any event immediately after elimination of the said objective reasons, which Ancillary
Assets shall, prior to IPO of the Company, meet the then applicable regulatory requirements for the Qualified IPO (as defined in the Shareholders Agreement) and requirements of the IPO intermediaries, and shall not create obstacles to the Qualified
IPO of the Company. 

  

	 	(7)	 After the Closing, the Company shall use commercially reasonable efforts to optimize terms of its existing and
future business contracts, with a view to achieve best interests of the Company; and if any such agreements contain any terms (if any) that create material obstacles to the Qualified IPO of the Company, the Company shall proactively communicate with
the counter parties to the relevant agreements, and adjust any terms (if any) under such agreements that create or may create material obstacles to the Qualified IPO of the Company in the manner acceptable to the then engaged IPO intermediaries of
the Company. 

  

	 	(8)	 Each member of the Management shall, through the Management Holdco, subscribe and hold its respective share of
the equity in the Company represented by US$3 million of the Company’s registered capital acquired by the Management Holdco hereunder, whose share of such equity shall be the proportion of its capital contribution obligations subscribed in
the Management Holdco to the total capital contribution obligations subscribed by all members of Management in the Management Holdco (hereinafter referred to as the “Share of Equity” of such member of the Management). The unit
subscription price of the Share of Equity subscribed by each member of the Management shall be US$1 for each unit equity of the Company represented by per US$1 registered capital of the Company. Each member of the Management shall pay RMB equivalent
to 25% of the total subscription price of its Share of Equity to the Management Holdco on every one (1) year anniversary of the Closing Date (calculated according to the USD to RMB central parity rate announced by the People’s Bank of
China on the day of payment), which payment shall be made in four (4) years; provided, however, if the Company’s listing plan requires the Management Holdco to pay up the registered capital subscribed by it in the Company in advance, all
members of the Management shall fully fulfil the capital contribution obligations in connection with their respective Share of Equity in advance. The Management Holdco shall, upon receiving any of the above-mentioned capital contribution from
members of the Management, immediately pay such capital contribution to the Company, so as to fulfil its capital contribution obligations to the Company. 

  
 17 

	 	(9)	 Prior to the Company’s application for Qualified IPO, the Company shall cooperate with the then engaged
intermediaries to eliminate the potential independence issues and fulfil the commitment on restructuring of the relevant business, personal, assets, etc. between the Company and the Group (excluding the Company and its Subsidiaries). The Group
shall, in accordance with requirements of this Agreement, use commercially reasonable efforts to transfer employment of the personal listed in Schedule 8 to the Company within the scheduled timelines. 

 

	 	(10)	 After the Closing, I-Mab HK and the Company shall cause the directors,
supervisor, Senior Officers of the Company and the controlling shareholder and actual controller (if any) of I-Mab HK to, prior to the Company’s application for Qualified IPO, cooperate with the then
engaged IPO intermediaries in eliminating circumstance that may constitute obstacles to the Qualified IPO such as potential horizontal competition etc.; transactions between the Company and its Affiliated Company(ies), and between the Company and
its directors, officers, managers, shareholders or other Affiliates, shall be conducted in compliance with requirements of relevant securities regulatory rules such as reasonableness, necessity, fairness, etc.. 

 

	 	(11)	 After the Closing, the Company shall construct the project of Hangzhou industrial base in accordance with the
applicable laws or requirements of Government Agencies, and shall, based on process of the construction, complete procedures required by the applicable laws such as relevant approval, registration or filing. 

 

	 	(12)	 After the Closing, the Company shall, within six (6) months, select the person in charge of clinical and
the person in charge of research and development (for the avoidance of doubt, the person in charge of research and development is also responsible for clinical) and sign labor contract, non-compete agreement
and intellectual property ownership agreement with such person. 

 Article 5 Representations and Warranties 

 

	5.1	 Company Representations and Warranties. The Company and
I-Mab HK jointly represent and warrant to the Investors as follows: except for the exceptional circumstances as disclosed by the Company to the Investors in the disclosure schedules attached hereto as
Schedule 9 (“Disclosure Schedules”, the specific items set forth in the Disclosure Schedules shall qualify the corresponding representations and warranties hereunder), the Company and
I-Mab HK make the following representations and warranties in connection with this Agreement on the Signing Date and the Closing Date of this Agreement (or, for representations and warranties made on a
specific date, such representations and warranties are deemed to be made on that specific date), and the Company and I-Mab HK acknowledge and agree that the Investors rely on the authenticity, completeness and
accuracy of these representations and warranties to sign this Agreement and consummate the transactions contemplated under this Agreement. 

  
 18 

	 	(1)	 Due Organization. The Company is a limited liability company established and validly established in
accordance with the conditions and legal procedures prescribed by the PRC laws. It has obtained all necessary approvals and permits from Government Agencies for its establishment. 

 

	 	(2)	 Constitutional Documents. The constitutional documents of the Company that have been delivered to the
Investors are true and complete. On the Signing Date and the Closing Date of this Agreement, the above-mentioned constitutional documents are valid and have not been replaced by other documents (provided that at Closing, such constitutional
documents will be superseded by the Amended Articles of Association). All legal and procedural requirements and other procedures related to the above-mentioned constitutional documents have been properly complied with and performed in accordance
with the law. 

  

	 	(3)	 Authorization and Enforceability. As of the Closing Date, this Agreement and the other Transaction
Documents are duly authorized, and with respect to the Agreement and the other Transaction Documents to which the Company and the Warrantor are parties, such agreements, after executed by the relevant parties, shall constitute valid and legally
binding agreements on the Company and the Warrantor. The form of this Agreement is lawful, and is enforceable upon the Company and the Warrantor. The Company or the Warrantor’s execution, delivery and perform of this Agreement and other
Transaction Documents to which it is a party, and the rights and obligations under such Transaction Documents, will not violate laws and regulations of the PRC nor the articles of association or other constitutional documents of the Company or the
Warrantor, will not violate court judgments, rulings, arbitral awards, administrative decisions, orders which are binding on or applicable to the Company or the Warrantor, and will not violate any document, contract or agreement to which the Company
or the Warrantor is a party. 

  

	 	(4)	 Capital Contribution. As of the Signing Date of this Agreement, the Company’s registered capital is
not paid in. 

  

	 	(5)	 Equity Ownership. The Warrantor has the title to the equity held by it, and there is no pledge or any
other incumbrance on the equity. Upon acquiring the relevant Target Equity and making capital contributions in accordance with this Agreement, the Investor shall obtain complete and valid ownership of such equity. Except as stipulated in this
Agreement and other Transaction Documents and as required by applicable laws, there is no pre-emptive rights, convertible securities or other outstanding equity commitments for issuance of additional equity or
other similar commitments in the Company’s registered capital. There is no effective control agreement or similar arrangement against the Company and its equity or assets. Except provided in the Shareholders Agreement and the articles of
association of the Company, the Company is not subject to any obligation to repurchase, redeem or otherwise purchase any equity. The Company is not subject to any legal or contractual obligation to provide any capital investment to any other person
(no matter in the form of loan, capital contribution or otherwise). 

  
 19 

	 	(6)	 Government Approval. As of the Closing Date, the Company has full power and authority to hold, lease or
operate its property (including without limitation Intangible Assets of the Licensed Pipelines) and operate its existing business (including without limitation the Licensed Pipelines), and has all the required approvals, permits, licenses,
certificates, consents, or other approval documents from government agencies (“Approval Documents”) for holding, leasing or operating its property (including without limitation Intangible Assets of the Licensed Pipelines) and
operating its existing business (including without limitation the Licensed Pipelines), there is no ongoing or potential government agency Approval Documents that may be suspended or revoked, unless the absence of such Approval Documents of the
government agency, or the potential revocation or cancellation of such Approval Documents from the government agency will not prevent the Company from fulfilling this Agreement or cause material negative effects. The Company has always complied with
the requirements of these Approval Documents, and has not violated these Approval Documents in any material respect. The Company has never received any written or oral notice from any government department informing it that it has violated any
provisions under any such Approval Documents. 

  

	 	(7)	 Company’s External Investment. The Company does not have any Subsidiaries, branches, or entities
that the Company invest in other forms, nor does it have any other investment commitments. 

  

	 	(8)	 Financial Statements; Off-Balance Sheet Liabilities. The Company
has delivered the unaudited Company’s balance sheet and related income statement and cash flow statement (hereinafter collectively referred to as “Management Statements”) as of the financial statement date (that is, 30 April,
2020). The Management Statements (a) are prepared based on the Company’s books and other financial records, (b) in material respects fairly reflect the Company’s financial status and operating results as of the financial
statement date or the corresponding period, and (c) have been prepared in accordance with China’s general accounting principles and following the principle of consistency in line with the Company’s previous practice.

 The Company does not have any other material off-balance sheet transactions,
debts, arrangements and obligations, including but not limited to relationships with non-consolidated reporting entities. 
  

	 	(9)	 Related Party Transactions. There are no material transactions between the Company and the Company
and/or Affiliated Companies and their directors, officers, managers, shareholders, or other related parties (hereinafter collectively referred to as “Related Parties”) that contain terms different from those terms entered into with
unrelated third parties based on the fair trade. As of the Closing Date, except for the Transaction Documents (including the agreement or documents required or contemplated by the Transaction Documents) and labour-related contracts, there is no
contract, agreement or other transaction between the Company and any Related Parties that is still within the validity period or has not been completed, and there are no due or outstanding debts, liabilities nor any other payables and receivables
with the Related Parties, except for those that will not cause Material Adverse Changes in the Company’s production and operation. 

  
 20 

	 	(10)	 No Material Adverse Change. From the financial statement date of the Company to the Closing Date, the
Company’s business operations are normal, specifically: 

  

	 	(a)	 There is no Material Adverse Change to the Company’s financial situation, assets, liabilities, and net
business value, except for changes in the ordinary course of operation; 

  

	 	(b)	 There are no strikes, labour disputes, or any new or continuation of events or circumstances that cause or may
cause Material Adverse Change to the Company; 

  

	 	(c)	 There is no cancellation or waiver of right that may have a material adverse impact on the business operations,
nor is there cancellation or waiver of any rights or claims with material value, nor is there cancellation or waiver of any rights or claims against Related Parties; 

 

	 	(d)	 No Material Adverse Change to the relationship between the Company and its suppliers, clients or customers has
occurred or may occur; 

  

	 	(e)	 No Material Adverse Change in the accounting or bookkeeping methods or accounting practices related to or
affecting the business of the Company has occurred; 

  

	 	(f)	 There is no sale, transfer or lease of any material property or asset (whether tangible or intangible), nor any
incumbrance created on such assets, and there is no payment, loan or prepayment obligation related to such material property or asset. 

  

	 	(11)	 Tax Matters. All tax statements, reports and forms (“Tax Reports”) that need to be
submitted by the Company have been provided to the competent government authorities in a timely manner, and all Tax Reports accurately reflect the Company’s tax burden in all material respects for the period, property, or event recorded. All
taxes, including tax in Tax Reports or taxes that any government agency believes shall be paid by the Company, or taxes levied on the Company’s property, assets, capital, turnover, or income have been paid in full (except for taxes fully
reserved in the relevant Tax Reports). At present, there is no unfinished or potential inspection, inquiry or audit by a competent department on the Company. The tax that the Company shall withhold in accordance with the law has been withheld and
handed over to the competent government agency, or the Company shall keep it properly. The Company does not have any material tax liability or obligation of any nature, unless such tax liability or obligation is (a) fully reflected in the Tax
Reports; or (b) occurs during the normal operating activities of the Company since its establishment. 

  
 21 

	 	(12)	 Property Ownership/No Incumbrance. Article 1.12 of the Disclosure Schedules lists all real
estate currently used by the Company. Except for the leased real estate, the Company has the complete and marketable rights of all other real estate (if any) listed in Article 1.12 of the Disclosure Schedules, and there is no liens or
other incumbrances over these rights. With respective to the leased real estate, all leases of the Company are fully effective; all the rent and additional payments due have been paid; since the beginning of the original lease period, the Company
has occupied properly, and there has not been any material violation of the provisions of the lease contract, nor has there been any material breach of contract or any event, situation or behaviour that may lead to violation of the lease contract.
The Company’s leased real estate is in good maintenance condition, and is sufficient to meet the current purpose of use (except for normal wear and tear). 

The Company legally owns the material tangible movable property (or have legal right to use such tangible movable property) required to engage
in the main business and is able to operate its tangible movable property independently. To the knowledge of the Company and the Warrantor, there is no contracts, agreements, commitments, documents or laws and regulations, government regulations,
government requirements, measures, litigation or other legal procedures that may affect the Company’s legal and complete ownership or use of its tangible movable property in material respects. To the knowledge of the Company and the Warrantor,
the Company’s use of the tangible movable property for business operation is in compliance with PRC laws and will not infringe the rights and interests of any third parties. 

 

	 	(13)	 Employees. The Company does not violate the applicable PRC labour laws in any material respects
(including but not limited to labour contracts, wages, working hours, social insurance and housing provident fund payment, etc.) nor is there any material liabilities, contingent liabilities or unpaid fees due to the requirements of applicable PRC
labour laws. The Company has paid withholding tax on behalf of the employees to the relevant Government Agency, or has withheld and reserved on behalf of its employee payable amount that is not yet due for these Government Agencies. The Company does
not have any material amounts of unpaid wages, taxes, penalties or any material payments due to violation of the above mentioned obligations. The Company does not have any unpaid economic compensation that should be paid for the termination of
labour relations or other material payment obligation for similar compensation or compensation costs related to the employment relationship. 

Except for social insurance and housing provident funds as required by the PRC laws, the Company has not participated and is not subject to
any other pension, retirement, profit sharing, deferred compensation or other employee benefit plan, arrangement, agreement or understanding, nor is there any other pension, retirement, profit sharing, deferred compensation, or other employee
benefit plan, arrangement, agreement, or understanding that any employee or former employee (or its beneficiaries, if any) has the right to participate in or enjoy. The Company has been paying social insurance and housing provident funds for all
employees in accordance with the law. 
 There are no pending labour controversy or disputes between the Company and its existing or former
employees, and to the knowledge of the Company and the Warrantor, there are no potential labour controversy or disputes, except those that will not cause Material Adverse Change to the Company’s business and financial conditions. 

  
 22 

 The Company currently has no intention to terminate the labour relationship with any Key
Employees. To the knowledge of the Company and the Warrantor, the Key Employees of the Company are not subject to any other contract (including licenses, commitments or other obligations) or decree, judgment, order of government agencies or courts
other than the contracts entered into with the Company, which materially impact the employee’s ability to serve the Company’s interests, or will be in conflict with the Company’s business. The Company has not entered into any
collective contract or similar contract or arrangement with employees. 
  

	 	(14)	 Material Contracts. Any Material Contract was executed under normal commercial conditions. Any Material
Contract is a contract that is valid and binding in accordance with its terms (except for those that cannot be enforced due to bankruptcy, liquidation, reorganisation or other similar laws that affect the general rights of creditors); there is no
violation or breach of any Material Contracts in material respects by the Company, nor is there any matter that will constitute a material breach of contract by the Company; the Group has not violated any agreement or arrangement in connection with
the Target Pipelines; the Company has not received any notice on termination or cancellation of any Material Contract or in connection with breach under any Material Contract; and to the knowledge of the Company and the Warrantor, there is no
violation or breach of any Material Contracts in material respects by the counter party(ies) thereof, nor is there any matter that will constitute a material breach of contract by the counter party(ies); in addition, the consummation of the
transaction contemplated in this Agreement will not (and will not give anyone the right to) terminate or modify the Company’s rights under any Material Contracts, or accelerate the performance or increase the Company’s obligations under
any Material Contracts, or create any liens or other incumbrances therefrom. 

 “Material Contracts”
refer to any material contracts to which the Company is a party, or involving any property or assets of the Company, including: (a) contract under which any party has obligation to pay RMB1,000,000 or more; (b) real estate lease contract;
(c) exclusive cooperation/license contract, or contract involving non-compete or other clauses that restrict or interfere with the Company’s capacity of operation in any manner or in any
jurisdiction; (d) contract stipulating line of credit; (e) contract stipulating securities provided by the Company; (f) contract granting power of attorney or similar authorization to any person; (g) contract involving right of
first refusal; (h) contract involving any transaction between the Company and its Related Party(ies); (i) collective contract or contract providing severance (except statutory severance) to any officers, directors or employees,
(j) contract that materially affects operation of the Company, or contract that is material to the Company’s operation; (k) contract stipulating that the Company shall make payment or provide benefits to third party(ies) as a result
of consummation of the transactions contemplated under this Agreement; (l) material license agreement (including agreement under which the Company licenses Intellectual Property to other person(s), and agreement under which the other person(s)
license Intellectual Property to the Company) or transfer agreement in connection with Intellectual Property; (m) contract that is not entered into in normal commercial terms; (n) contract to transfer, sell or dispose of material assets of
the Company; (o) contract involving equity sale, equity acquisition, investment, financing, joint venture, merger and acquisition, restructure, profit sharing or change in control; (p) contract that creates incumbrances on the equity or
material property of the Company; (q) strategic cooperation agreement entered into with any partner that is material to the operation and development of the Company; and (r) any memorandum of understanding, letter of intent, contract or
agreement entered into with government departments (including enterprises solely owned or controlled by the State). 

  
 23 

	 	(15)	 Intellectual Property. 

 

	 	(a)	 As of the Closing Date, the Company and I-Mab HK have obtained all
proper Intellectual Property or relevant license in connection with business operation and the Licensed Pipelines, and have the complete and valid rights to own all Intellectual Property or relevant licensed rights necessary to own and operate the
Licensed Pipelines, and to the knowledge of the Company, I-Mab HK and the Management, there are no disputes on such rights. 

 

	 	(b)	 As of the Closing Date, all Intellectual Property in connection with the business operation of the Company and
the Licensed Pipelines are legally and beneficially owned by the Company or legally used with the permission of the owner(s) (as the case may be), and there are no incumbrances over such Intellectual Property. The Company’s Intellectual
Property is sufficient to enable it to operate its business in its current state. 

  

	 	(c)	 Article 1.15 of the Disclosure Schedules sets forth a complete and accurate list of Intellectual
Property registered under the Company’s name and Intellectual Property licensed to the Company under Intellectual Property licensing. To the knowledge of the Company, I-Mab HK and the Management as of the
Signing Date and the Closing Date, there are no notices, statements, claims, opposition, cancellation or litigation by third parties that allege the Intellectual Property used by the Company as invalid. 

 

	 	(d)	 All licenses of Intellectual Property used by the Company are fully effective. The Company has not, as of the
Signing Date and the Closing Date, breached any of the material terms of the licences, and the counter party(ies) to the licences have not stated in writing that it will breach the contract. 

 

	 	(e)	 To the knowledge of the Company and the Warrantor as of the Signing Date and the Closing Date, the Company has
not interfered with, infringed, improperly used or violated the Intellectual Property of third parties due to the use of Intellectual Property or licensed Intellectual Property, nor has it received any allegations, complaints, claims, demands or
notices claiming any such interference, infringement, improper use or violation. In addition, to the knowledge of the Company and the Warrantor, no third party has interfered with the Company’s Intellectual Property, or infringed, improperly
used or violated the same. 

  
 24 

	 	(16)	 Litigation. There are no pending or threatened litigation, arbitration or other legal proceedings
against the Company or its property or rights by any court or arbitral tribunal, and there are no pending or threatened administrative or other proceedings by any Government Agency (including investigations by such Government Agency), which may
cause Material Adverse Changes to the Company’s right or ability to continue its current business, or to the Company’s financial or other conditions, property or assets; there is no valid basis for initiating such litigation, arbitration,
legal proceedings, administrative and other procedures or investigations. The Company is not bound by any judgment, order or ruling made in any litigation, arbitration or other legal proceedings that may cause material adverse changes to its
operations. The Company has not received any notice of material disputes or claims under any contract. 

  

	 	(17)	 Compliance. The Company has not (a) materially violated the law, (b) materially violated
approval of any relevant Government Agency, (c) violated the provisions of its articles of association, or (d) failed to perform or comply with any material obligations, agreements, covenants or conditions in any contract on which it is a
party or which binds it or any of its property. The Company has not received any notification of such breach of contract, violation or omission, whether have occurred or may occur. 

 

	 	(18)	 Books and Records. The Company’s books and records are true and accurate in all material respects,
without any material inaccuracies or inconsistencies, and are prepared and maintained in accordance with applicable laws and good business practices, so as to enable the Company to prepare its financial statements in accordance with the generally
accepted accounting principles of the PRC. The Company’s meeting minutes book accurately reflects in all material aspects all the important actions and legal procedures that have been taken by the Company’s shareholders and the Board of
Directors as of the record date. 

  

	 	(19)	 External Shareholdings by Senior Officers. Except as expressly stated in Article 1.19 of the
Disclosure Schedules, to the knowledge of the Company and the Warrantor, no Senior Officers or Key Employees of the Company directly or indirectly own, manage, control, or invest in any business that competes with the business of the Company
(“Competing Business”), act as a director, management, advisor or employee of any company or entity engaged in such business, or hold any equity or share in any company or entity engaged in such business (except holding not more
than 5% of all outstanding shares of a listed company). 

  

	 	(20)	 Disclosure. All documents, materials and information provided by the Company in the course of due
diligence by the Investors are true, accurate, complete and valid, and are not misleading. Documents, statements and information related to the Company that would be reasonably expected to materially affect the Investors’ intention to
consummate the transaction contemplated hereunder have been disclosed to the Investors without material omissions. 

  
 25 

	5.2	 Investors Representations and Warranties. Each Investor separately but not jointly represents and
warrants to Other Parties as follows: 

  

	 	(1)	 Due Organization. Such Investor is a [limited partnership or limited liability company] established and
validly existing under the PRC laws. 

  

	 	(2)	 Authorization and Enforceability. This Agreement is duly authorized, and after executed by the Parties,
shall constitute a valid and legally binding agreement on the Investor. The form of this Agreement is lawful, and is enforceable upon the Investor in the PRC. 

Article 6 Transitional Period Covenants 
  

	6.1	 Business Operation 

 

	 	(1)	 The Company covenants that from the Signing Date of this Agreement to the Closing Date, except for implementing
the transactions contemplated hereunder, the Company and the Management shall take, and I-Mab HK shall procure the Company and the Management to take the following actions: 

 

	 	(a)	 In the normal course of business, conduct business in a manner that is in compliance with Applicable Laws and
is consistent with past practices and prudent business practices; 

  

	 	(b)	 Ensure the integrity of the existing business organisation; 

 

	 	(c)	 Maintain all operating assets and equipment (including any owned or licensed Intellectual Property) in normal
operation and good maintenance; 

  

	 	(d)	 Renew and update registered Intellectual Property rights in the normal course of business;

  

	 	(e)	 Promptly notify the Investors of any material violation of the Company and the Warrantor’s representations
and warranties, or any material violation of other terms of this Agreement. 

  

	 	(2)	 The Company, the Warrantor and the Management covenant that from the Signing Date of this Agreement to the
Closing Date, except for implementing the transactions contemplated hereunder, none of the Company or its shareholders or the Management shall take any of the following actions without the Investors’ prior written consent:

  

	 	(a)	 Terminate the operation of the Company’s existing business or substantially change any part of its
business behaviour; 

  

	 	(b)	 Sell or dispose of all or most of the Company’s intangible assets or assets; 

 

	 	(c)	 Distribute any profits among shareholders through payment of dividends, capitalization of capital reserve or
otherwise; 

  

	 	(d)	 Create or amend terms and conditions of any employee equity incentive plan without the written consent of the
Investors; 

  

	 	(e)	 Amend the Company’s previously adopted financial rules or change the Company’s fiscal year;

  
 26 

	 	(f)	 Increase or reduce registered capital, change of equity (except for matters for purposes of the transactions
contemplated hereunder), or attract any investment or obtain any investment commitments other than those contemplated hereunder; 

  

	 	(g)	 Change the company form; 

 

	 	(h)	 Sell, transfer, licence, mortgage, create any incumbrance or otherwise dispose of any trademarks, patents,
copyrights or other Intellectual Property owned by the Company; 

  

	 	(i)	 Adopt any resolution to terminate the Company or conduct any merger, division, bankruptcy, reorganization,
liquidation, dissolution or designation of receiver or similar events of the Company; 

  

	 	(j)	 Except for purpose of performing this Agreement, amend or restate the Company’s articles of association;

  

	 	(k)	 Except for purpose of performing this Agreement, approve any transfer of equity of the Company; or

  

	 	(l)	 Enter into commercial cooperation with any third party on the Pipelines to be injected into the Company,
including but not limited to joint development, external licensing and other cooperation. 

  

	6.2	 Exclusivity. The Company, the Warrantor and the Management covenant that from the Signing
Date of this Agreement to the earlier to occur of: (1) the Closing Date; (2) the date of termination of this Agreement, without the Investors’ prior written consent or unless otherwise agreed in this Agreement, the Company, the
Warrantor and the Management may not, and shall procure their Affiliates and their respective directors, supervisors, officers, employees, representatives or agents not to: 

 

	 	(1)	 Initiate, induce or instigate sale or other disposal of equity in the Company, or any inquiry, quotation or
offer related to acquisition or merger of the Company (each referred to as an “Alternative Transaction”); 

  

	 	(2)	 Participate in any discussions or negotiations on any Alternative Transactions, or provide or disclose any
information about the Company or the business for any Alternative Transactions; or 

  

	 	(3)	 Enter into any binding or non-binding written or oral agreement,
arrangement or understanding for any Alternative Transactions. 

  

	6.3	 Notification of Specific Matters. Each Party to this Agreement covenants that from the
Signing Date to the Closing Date of this Agreement, it shall notify the Other Parties and provide the corresponding supporting documents immediately after knowledge of the following matters: 

 

	 	(1)	 Any facts or circumstances that constitute a material violation of its representations and warranties made in
this Agreement; or 

  
 27 

	 	(2)	 Become aware of the occurrence of certain facts or circumstances after the Signing Date of this Agreement, and
the occurrence of these facts or circumstances will or may cause material violation of such representations and warranties made by the Party. 

Article 7 Other Agreements and Covenants 
  

	7.1	 Equity Incentive Plan. The Parties agree that, within five (5) months after the
Closing, the Company will implement its employee equity incentive plan (the “ESOP”) based on all ESOP Target Equity held by the ESOP Holdco. For such ESOPs: (a) the unit exercise price for equity represented by per US$1 of
registered capital is the RMB equivalent of US$1, (b) subject to the grantees of incentives continuing to work in the Company and passing the relevant annual performance assessment tests, 50% of the relevant award granted under the ESOP will be
vested on the two (2) years’ anniversary of the grant date (i.e. the date when the Company and the grantee of incentives signed the equity incentive award document), and 100% of the relevant award will be vested on the three
(3) years’ anniversary of the grant date; however, upon occurrence of a Deemed Liquidation Event (as defined in the Shareholders Agreement), all unvested award then held by the grantees of equity incentive will be fully vested. Adoption
and amendment of the ESOP and its specific implementation plan shall be subject to approval by a majority of members of the Company’s Board of Directors (including consent of both Director Investors). The Parties hereby acknowledge and agree
that any equity of the Company held by the ESOP Holdco may only be used for issuance of equity incentives under the ESOP in accordance with the decision of the Board of Directors, and except for the purpose of implementing the ESOP and upon
resolution of the Board of Directors, the ESOP Holdco shall not directly or indirectly transfer, pledge, create incumbrance or otherwise dispose of any equity of the Company by it. 

 

	7.2	 Protection of Intellectual Property. After the Closing, the Company shall exert all
commercially reasonable efforts to obtain lawful ownership or right of use of Intellectual Property (including but not limited to patents, trademarks, copyrights, know-how, domain names and trade secrets,
etc.) required for the Company’s business and operation activities, and exert all efforts to protect the Company’s Intellectual Property from infringement by any third party. 

 

	7.3	 Operation in Compliance with Laws. After the Closing, the Company shall comply with
relevant Applicable Laws in all material aspects, continuously improve corporate governance of the Company in various aspects (including without limitation clinical trials, human generic resources, environmental protection, health and security,
finance, labour, Intellectual Property, social insurance, housing provident fund, taxes and business) and maintain the validity of the licenses required to operate its business. If, after the Closing Date, in accordance with the relevant Applicable
Laws or the requirements of Government Agencies, there is a need to obtain relevant concessions, licenses, permits, approvals, waivers, consents, authorisations, registrations or filings (“Government Licenses”) for any matter or
action involved in the Company’s business or its business operations, the Company shall take all necessary measures and actions to obtain such Government Licenses in a timely manner. The Company shall maintain insurance for its business and
Target Pipelines in compliance with the laws. 

  
 28 

	7.4	 Tax Payment. Each Party shall be responsible for the taxes in connection with the
transactions contemplated hereunder on which it is levied or which it is responsible to pay. For the avoidance of any doubt, the Parties further acknowledge that notwithstanding the foregoing, if the Investors are imposed on extra taxes in
connection with these transactions (i.e. taxes in connection with these transactions except stamp tax) as a result of the Equity Transfer of these transactions, I-Mab HK shall indemnify the Investors against
such extra taxes. The Company will conduct business operation in compliance with the laws and regulations, and shall not engage in any activities or behaviours that involve violations of laws and regulations, including but not limited to any
violations of laws and regulations related to taxation and tax collection. 

 Article 8 Liability for Breach of
Contract; Indemnification. 
  

	8.1	 Breach of Contract. If any Party fails to duly or fully fulfil its obligations, covenants
or other agreements under this Agreement or other Transaction Documents, or the representations and warranties made by the Party under this Agreement and other Transaction Documents are untrue, inaccurate or incomplete, then such Party shall be
regarded as having breached the contract. 

  

	8.2	 Liability for Breach of Contract; Indemnification. When the breach of contract described
in Article 8.1 above occurs, the breaching Party shall indemnify the non-breaching Parties for any direct losses suffered by the non-breaching Parties as a result of the
breach by the breaching Party (“Loss”). The breaching Party’s indemnification against the non-breaching Parties’ Loss or its taking of liability for breach shall not affect the non-breaching Parties’ right to require the breaching Party to continue to perform the Agreement or their rights to terminate this Agreement. For the avoidance of any doubt, in the event the Company fails to
close a Qualified IPO within four (4) years after the Closing Date of these transactions as a result of any Party’s rejection to perform its obligations, covenants or other agreement under this Agreement or under other Transaction
Documents to resolve issues of horizontal competition and/or related party transactions to the extent such issues create obstacles to the Qualified IPO, then if the Investors are non-breaching Parties,
notwithstanding provisions of Article 3.5 of the Shareholders Agreement, the repurchase price which the Investors are entitled to will be the higher of the repurchase price set forth in Article 3.5 of the Shareholders Agreement, and the value of
relevant equity based on appraisal by an appraiser to be jointly designated by the Parties at that time; or if the shareholders other than the Investors are non-breaching Parties, the breaching Party shall
indemnify the non-breaching Parties against Losses incurred by them. 

 Article
9 Effectiveness, Amendment and Termination of this Agreement 
  

	9.1	 Effectiveness. This Agreement shall take effect on the date when it is executed by the
Parties or their authorised representatives (Chinese legal persons and unincorporated organizations must also affix their official seals). 

  

	9.2	 Amendment. Any amendment or alteration to this Agreement shall be negotiated by all
Parties, and shall be effective only after a written contract on such amendments or alteration have been signed by the Parties 

  

	9.3	 Termination. This Agreement may be terminated prior to the Closing Date under any of the
following circumstances: 

  

	 	(1)	 With the unanimous written consent of all Parties; 

  
 29 

	 	(2)	 Terminated pursuant to Article 3.2; 

 

	 	(3)	 Any Party breaches this Agreement as described under Article 8 hereof, and does not cure the breach within
thirty days (30), or the breach have occurred for twice or more cumulatively, then the non-breaching Parties shall have the right to unilaterally terminate this Agreement; 

 

	 	(4)	 If force majeure occurs and as a result the fundamental purpose of this Agreement cannot be achieved, any Party
may terminate this Agreement. 

  

	9.4	 Effect of Termination. When this Agreement is terminated in accordance with Article 9.3,
except Article 1 (Definitions), Article 8 (Liability for Breach of Contract; Indemnification), Article 10 (Miscellaneous) and this Article 9.4, this Agreement shall be invalid and shall no longer be binding or effective on the Parties who terminate
the Agreement, and such Parties will be no longer required to bear the responsibilities and obligations under this Agreement; provided, however, despite termination of this Agreement, a Party shall still be liable for any losses incurred by the
Other Parties as a result of its breach of this Agreement before the termination. For the avoidance of any doubt, in case of termination due to circumstances under Article 9.3(2) or Article 9.3(3) hereof, such termination of the Agreement shall take
effect only between the Investor(s) to who such termination is related and the Company, and effectiveness of the Agreement between the other Investor(s) and the Company shall not be impacted; in such case, this Agreement shall be correspondingly
adjusted so as to remove the Investors to whom the termination is related. 

 Article 10 Miscellaneous 

 

	10.1	 Fees. The Investors shall respectively bear their own transaction costs that are incurred
by the Investor due to transactions contemplated under this Agreement, including but not limited to, professional services fees incurred by the Investors and their consultant (including but not limited to accountants, lawyers, etc.) to carry out due
diligence, draft Transaction Documents, or participate in negotiations; provided, however, the Company agrees that, (a) if the Closing is completed successfully, or (b) if the Closing fails to occur due to reasons attributable to the
Company, then the Company will bear the Investors’ transaction costs up to an aggregate amount of RMB Six Hundred Thousand (600,000) Yuan. For the avoidance of doubt, if multiple Investors conduct due diligence at the same time, the relevant
costs that may be borne by the Company shall only be calculated once, and the amount of the transaction costs of all Investors that may be borne by the Company shall not exceed RMB [Six Hundred Thousand (600,000)] Yuan in the aggregate. Subject to
the Company’s receipt of a legal invoice for the relevant fees provided by a third party service organisation designated by the Investors, the Company will pay such fees to the third party service organisation designated by the Investors.

  

	10.2	 Notice. 

 

	 	(1)	 All notices, claims, requests, consents, waivers and other communications required or permitted under this
Agreement shall be in writing (including telegram, fax or similar written form) and shall be sent, delivered or mailed, e-mailed or faxed to the following addresses: 

  
 30 

					
	Company:	  	I-Mab Biopharma (Hangzhou) Co., Ltd.
	  	 Attention:
  

Phone:
  

E-mail:
  

Address:
  
	  	 [REDACTED]
  

[REDACTED]
  

[REDACTED]
  

[REDACTED]

		
	I-Mab HK:	  	I-MAB BIOPHARMA HONGKONG LIMITED
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
	Investors:	  	Hangzhou Fushi Investment Management Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	Fax:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Shenzhen Tsingsong Shengrui Investment Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Nanjing Tsingsong Healthcare Investment Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]

  
 31 

					
		  	Hangzhou Heda Biotech Investment Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Xiamen Ronghui Derong Equity Investment Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	Fax:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Ningbo Yanyuan Yaoshang Chanrong Equity Investment Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Ningbo Yanchuang Yaoshang Yangming Investment Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]

  
 32 

					
		  	Jiangsu Yanyuan Dongfang Investment Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Ningbo Rongshun Yanyuan Investment Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Zhuzhou Guochuang Junyao Investment Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Ningbo Hanhai Qianyuan Equity Investment Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Hangzhou Haibang Yigu Investment Partnership (Limited Partnership)/Jialiang Shan
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]

  
 33 

					
		  	Zhejiang Silu Industry Investment Fund Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	Fax:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Viva Biotech (Shanghai) Ltd.
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	Fax:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Tianjin Huatian Enterprise Management Consultation Limited Partner (Limited Partner)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
	Management / Management Holdco:	  	
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]

  
 34 

					
		
	ESOP Holdco:	  	
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]

  

	 	(2)	 Each notice, request or other communication delivered or served in accordance with the provisions of Article
10.2(1) shall be deemed as delivered or served as follows: (a) if sent by a courier company or personally delivered, it shall be deemed as delivered when the relevant notice, request or communication is sent to the above-mentioned address;
(b) if sent by fax, then the relevant notice, request or communication shall be deemed as delivered when it is transmitted to the above fax number and the report of successful fax transmission is obtained; (c) if sent by e-mail, it shall be deemed as delivered twenty-four hours after the date on which the e-mail containing the relevant notice, request or communication as recorded by the
sender’s computer is sent, provide, however, if the sender does not receive the recipient’s confirmation of receipt of the above e-mail within twenty-four hours (except for automatic email
confirmation of receipt), the above notice, request or other communication shall be sent by courier or fax by the end of the same day. 

  

	10.3	 Governing law. This Agreement shall be governed by and be construed in accordance with the
PRC laws. 

  

	10.4	 Dispute Resolution. In the event of is a dispute over the interpretation or performance of
this Agreement, the Parties shall firstly attempt to resolve the dispute through friendly consultation. If the dispute cannot be resolved through consultation within thirty (30) days after one Party delivers written notice to the Other Parties
requesting the commencement of consultation, then any Party may submit the dispute to the China International Economic and Trade Arbitration Commission for arbitration, and the arbitration shall be conducted in Hangzhou according to the said
commission’s arbitration rules then in force. The arbitration award shall be final and binding on all Parties and cannot be appealed. The arbitration costs shall be borne by the losing party unless the arbitration award provides otherwise. When
any dispute occurs and when any dispute is under arbitration, except the matter under disputes, the Parties shall continue to exercise their other rights and perform their other obligations under this Agreement. 

 

	10.5	 Confidentiality. Each of the Parties shall not, and shall cause its respective Affiliates,
shareholders, directors, officers, employees, representatives or agents not to, directly or indirectly disclose the existence of this Agreement or any information related to the transactions contemplated hereunder (including any information obtained
by the Party during the course of the negotiation and execution of this Agreement), unless (a) it has obtained the prior written consent of the non-disclosing Parties, or (b) such information is
required to be disclosed by the applicable laws and is only disclosed to the extent necessary to comply with the applicable laws or any regulations or policies of any stock exchange, provided, however that the disclosing Party shall, within a
reasonable time before the disclosure or submission of the relevant information, seek opinions of the Other Parties on such disclosure and submission, and that if required by the Other Parties, the disclosing Party shall seek for confidential
treatment of the disclosed or submitted information to the extent possible. Before the Closing, without the written consent of the Investors, the Company shall not disclose the investment that the Investors intend to make to the Company according to
this Agreement to the public through press conferences, industry or professional media, marketing materials or other means; however, each Investor has the right to disclose to the investors of its fund or its consultant in a non-public manner about the investment that such Investor intends to make in the Company under this Agreement, provided that the recipients shall have agreed to maintain the confidentiality of the relevant
confidential information. Notwithstanding the foregoing, I-Mab 天境生物, I-Mab HK’s parent company, being a company listed in the United
States, shall have the right to disclose the Company’s financing information in accordance with the requirements of U.S. securities laws without the need for separately obtaining the Parties’ consent. After the Closing, each of the
Company, I-Mab HK and the Investors shall have the right to disclose the existence of the Investors’ investment in the Company to third parties or the public; provided, however, the Investors shall seek
the opinions of I-Mab HK when disclosing information related to the Company’s investment matters, with a view to comply with the information disclosure requirements under the U.S. securities laws.

  
 35 

	10.6	 Severability. The obligations under this Agreement shall be regarded as separate
obligations and be independently enforceable. When one or more obligations of this Agreement are unenforceable, the enforceability of other obligations shall not be affected. If this Agreement is not enforceable against any Party, the enforceability
of this Agreement among the Other Parties shall not be affected. If one or more of the provisions of this Agreement are found to be invalid, illegal or unenforceable in any respect according to any applicable law, or a government agency requests
amendment of one or more provisions of this Agreement, the validity, legality and enforceability of the remaining provisions shall not be affected or damaged in any way. The Parties shall endeavour to replace these invalid, illegal or unenforceable
provisions with valid provisions through sincere consultations, and the economic effects of such valid provisions shall be as similar as possible to those of the invalid, illegal or unenforceable provisions. 

 

	10.7	 Entire Agreement. This Agreement (including the other Transaction Documents and any other
documents referred to or contemplated hereunder or thereunder) constitutes the entire agreement among the Parties with regard to the subjects hereof, and supersedes any other agreements or intentions previously reached by the Parties on the same
subjects. 

  

	10.8	 Assignment. Prior to completion of its capital contribution obligations, an Investor may
assign its rights and obligations under this Agreement to its Affiliates, and such assignment does not require prior consent of Other Parties or the Company. After completion of its capital contribution obligations, an Investor has the right to
assign its rights and obligations under this Agreement to any third party along with the sale or transfer (if any) of its equity in the Company to such third party; provided, however, such equity transfer shall be subject to the other
Investors’ right of first refusal under the Shareholders Agreement. Notwithstanding anything to the contrary herein, after completion of its capital contribution obligation, any Investor may transfer its then effective rights and obligations
under the Agreement to its Affiliates along with the sale or transfer (if any) of its equity in the Company, which transfer or assignment shall not be subject to any other shareholders’ consent, right of first offer, right of first refusal, co-sale rights or similar rights. Except the foregoing, without the prior written consent of each other Party, no Party shall assign its rights or obligations under this Agreement; any assignment without the Other
Parties’ consent shall be invalid. 

  
 36 

	10.9	 Counterparts. This Agreement is written in Chinese. This Agreement shall be signed in
thirty (30) original copies. Each Party shall hold one (1) original copy, and the remaining original copies shall be held by the company. Each copy of this Agreement shall be equally effective. 

 

	10.10	 Priority. If, in order to request any government agency to carry out any specific act,
separate agreements in connection with the transactions contemplated hereunder (including but not limited to, equity transfer agreement, the Company’s articles of association or amendments to the articles of association, as may be amended from
time to time, etc.) have to be signed in accordance with the standard templates or requirements of the government agency, this Agreement shall control over any such agreements, and such agreements shall only be used to request the government agency
to implement the specific act, and shall not be used to establish or as an evidence of any rights or obligations of the relevant parties on matters that may be stipulated in such agreements. 

(No text below) 

  
 37 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
  

	
	Company:
	
	I-Mab Biopharma (Hangzhou) Co., Ltd.
	(Seal)
	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 I-Mab HK: 

I-MAB BIOPHARMA HONGKONG LIMITED 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Hangzhou Fushi Investment Management Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Shenzhen Tsingsong Shengrui Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Nanjing Tsingsong Healthcare Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Hangzhou Heda Biotech Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Xiamen Ronghui Derong Equity Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Ningbo Yanyuan Yaoshang Chanrong Equity Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Ningbo Yanchuang Yaoshang Yangming Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Jiangsu Yanyuan Dongfang Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Ningbo Rongshun Yanyuan Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Ningbo Yanyuan Innovation Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Zhuzhou Guochuang Junyao Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Hangzhou Haibang Yigu Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Jialiang Shan 
 (Seal) 

 

	
	 /s/ Jialiang Shan

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Zhejiang Silu Industry Investment Fund Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Viva Biotech (Shanghai) Ltd. 
 (Seal) 

 

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Tianjin Huatian Enterprise Management Consultation Limited Partner (Limited Partner) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Management: 

Lili Qian 
  

	
	 /s/ Lili Qian

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Management: 

Zhengsong Zhang 

	
	
	/s/ Zhengsong Zhang

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Management: 

Yunfei Zhang 
  

	
	 /s/ Yunfei Zhang

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Management: 

Lihong Lou 
  

	
	 /s/ Lihong Lou

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Management: 

Kai Zhou 
  

	
	 /s/ Kai Zhou

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Management: 

Fang Yin 
  

	
	 /s/ Fang Yin

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Hangzhou Yijing Biotech Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  
 Signature Page to Equity
Transfer and Investment Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Hangzhou Lanjing Biotech Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  
 Signature Page to Equity
Transfer and Investment Agreement 

 Schedule 1: 

List of Target Assets 
 1. Target Assets to
be transferred to the Company on or before Closing Date: 
  

									
	 Asset Name
	  	 Rights of

Indications to
 Be

Transferred
 to
Company
	  	 Source
	  	 Territory of

License
	  	 Classification

for Drug

Registration

	TJ301	  	All indications licensed under TJ301 Agreement (i.e. “any indication for medicinal use in humans”)	  	Licensed from Ferring Pharmaceuticals	  	Greater China and the Republic of Korea	  	Therapeutic biological products - Class 1 - innovative biological products
					
	TJL1A3	  	All indications under TJL1A3 Agreement (i.e. “all uses and indications”)	  	Co-development with ABL BIO	  	Greater China	  	Therapeutic biological products - Class 1 – innovative biological products
					
	TJ102	  	All indications licensed under TJ102 Agreement (i.e. “treatment of any disease”)	  	Licensed from GENEXINE, INC.	  	Greater China, except Macau S.A.R.	  	Therapeutic biological products - Class 1 – innovative biological products

  
 Schedule 1 

 2. Target Assets to be transferred to the Company after Closing Date: 

 

									
	 Pipeline Name
	  	 Rights of

Indications to
 Be

Transferred
 to
Company
	  	 Source
	  	 Territory of

Rights
	  	 Classification

for Drug

Registration

	TJM2	  	All indications except COVID-19/CRS	  	Developed by I-Mab Group	  	Global	  	Therapeutic biological products - Class 1 – innovative biological products
					
	TJA3	  	All indications	  	Developed by I-Mab Group	  	Global	  	Therapeutic biological products - Class 1 – innovative biological products
					
	TJT6	  	All indications	  	Developed by I-Mab Group	  	Global	  	Therapeutic biological products - Class 1 – innovative biological products

  
 Schedule 1 

 Schedule 2: 

Shareholding Structures of the Company 

Before Completion of the Transactions 
  

									
	 Name of Shareholder
	  	Amount of
Registered Capital
Subscribed
(unit: USD)	 	  	Shareholding
Percentage	 
	 I-MAB BIOPHARMA HONG KONG LIMITED
	  	 	30,000,000	 	  	 	100	% 
	 Total
	  	 	30,000,000	 	  	 	100	% 

 After Completion of the Transactions 

 

									
	 Name of Shareholders
	  	Amount of
Registered Capital
Subscribed
(unit: USD)	 	  	Shareholding
Percentage	 
	 I-MAB BIOPHARMA HONGKONG LIMITED
	  	 	13,500,000	 	  	 	45	% 
	 Hangzhou Fushi Investment Management Partnership (Limited Partnership)
	  	 	2,500,000	 	  	 	8.33	% 
	 Shenzhen Tsingsong Shengrui Investment Partnership (Limited Partnership)
	  	 	1,655,000	 	  	 	5.52	% 
	 Nanjing Tsingsong Healthcare Investment Partnership (Limited Partnership)
	  	 	845,000	 	  	 	2.82	% 
	 Hangzhou Heda Biotech Investment Partnership (Limited Partnership)
	  	 	2,000,000	 	  	 	6.67	% 
	 Xiamen Ronghui Derong Equity Investment Partnership (Limited Partnership)
	  	 	1,000,000	 	  	 	3.33	% 
	 Ningbo Yanyuan Yaoshang Chanrong Equity Investment Partnership (Limited Partnership)
	  	 	200,000	 	  	 	0.67	% 
	 Ningbo Yanchuang Yaoshang Yangming Investment Partnership (Limited Partnership)
	  	 	320,000	 	  	 	1.07	% 
	 Jiangsu Yanyuan Dongfang Investment Partnership (Limited Partnership)
	  	 	280,000	 	  	 	0.93	% 
	 Ningbo Rongshun Yanyuan Investment Partnership (Limited Partnership)
	  	 	250,000	 	  	 	0.83	% 
	 Ningbo Yanyuan Innovation Investment Partnership (Limited Partnership)
	  	 	250,000	 	  	 	0.83	% 
	 Zhuzhou Guochuang Junyao Investment Partnership (Limited Partnership)
	  	 	700,000	 	  	 	2.33	% 
	 Ningbo Hanhai Qianyuan Equity Investment Partnership (Limited Partnership)
	  	 	700,000	 	  	 	2.33	% 
	 Hangzhou Haibang Yigu Investment Partnership (Limited Partnership)
	  	 	300,000	 	  	 	1	% 
	 Jialiang Shan
	  	 	300,000	 	  	 	1	% 
	 Zhejiang Silu Industry Investment Fund Partnership (Limited Partnership)
	  	 	300,000	 	  	 	1	% 
	 Viva Biotech (Shanghai) Ltd.
	  	 	200,000	 	  	 	0.67	% 
	 Tianjin Huatian Enterprise Management Consultation Limited Partner (Limited Partner)
	  	 	200,000	 	  	 	0.67	% 
	 Hangzhou Yijing Biotech Partnership (Limited Partnership)
	  	 	3,000,000	 	  	 	10	% 
	 Hangzhou Lanjing Biotech Partnership (Limited Partnership)
	  	 	1,500,000	 	  	 	5	% 
	 Total
	  	 	30,000,000	 	  	 	100	% 

  
 Schedule 2 

 Schedule 3: 

Key Employees List 

  
 Schedule 3 

 Schedule 4: 

Closing Certificate 

  
 Schedule 4 

 Schedule 5: 

Shareholders Resolutions 

  
 Schedule 5 

 Schedule 6: 

Shareholders Agreement 

  
 Schedule 6 

 Schedule 7: 

Amended Articles of Association 

  
 Schedule 7 

 Schedule 8: 

Employees Transfer Plan 

  
 Schedule 8 

 Schedule 9: 

Disclosure Schedules 

  
 Schedule 9EX-10.21

 Exhibit 10.21 

THE SYMBOL “[REDACTED]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN 

EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE 

COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 

I-Mab Biopharma (Hangzhou) Co., Ltd. 

 
  

Shareholders Agreement 
  

 
 September 15,
2020 

 Table of Contents 

 

							
	 Article 1
	 	Information and Inspection Rights	  	 	- 4 -	 
			
	 Article 2
	 	Equity Lockup	  	 	- 5 -	 
			
	 Article 3
	 	Investors’ Preferred Rights	  	 	- 6 -	 
			
	 Article 4
	 	Corporate Governance	  	 	- 13 -	 
			
	 Article 5
	 	Act in Concert	  	 	- 16 -	 
			
	 Article 6
	 	Liability for Breach of Contract; Indemnification	  	 	- 17 -	 
			
	 Article 7
	 	Effectiveness, Amendment and Termination of the Agreement	  	 	- 17 -	 
			
	 Article 8
	 	Miscellaneous	  	 	- 18 -	 
	
	 Schedule 1 Shareholding Structure Immediately After Completion of the
Transactions
	  

	
	 Schedule 2 List of Management Members to Join After the Closing Date
	  

	
	 Schedule 3 List of Competitors of the Company
	  

 SHAREHOLDERS AGREEMENT 

This SHAREHOLDERS AGREEMENT (this “Agreement”) is entered into in the PRC on September 15, 2020 (the “Signing Date”) by
and among the following parties: 
  

	1.	 I-Mab Biopharma (Hangzhou) Co., Ltd., a limited liability
company legally established and existing in accordance with the PRC laws, whose unified social credit code is 91330100MA2GNANB49 (the “Company” or “Project Company”); 

 

	2.	 I-MAB BIOPHARMA HONG KONG LIMITED, a company limited by law
established in accordance with the laws of the Hong Kong Special Administrative Region of the PRC, whose registration number is 2400410 (“I-Mab HK”) ; 

 

	3.	 Hangzhou Fushi Investment Management Partnership (Limited Partnership)
(杭州赋实投资管理合伙企业(有限合伙)), a limited partnership legally established and existing in accordance with
the PRC laws, whose unified social credit code is 91330102MA2AYYBD4Q (“Fushi Capital”); 

  

	4.	 Shenzhen Tsingsong Shengrui Investment Partnership (Limited
Partnership)(深圳市青松晟睿投资合伙企业(有限合伙)), a limited partnership legally established and existing in
accordance with the PRC laws, whose unified social credit code is 91440300MA5FYAQD4R (“Tsingsong Shenzhen”); 

  

	5.	 Nanjing Tsingsong Healthcare Investment Partnership (Limited
Partnership)(南京清松医疗健康产业投资合伙企业(有限合伙)), a limited partnership legally
established and existing in accordance with the PRC laws, whose unified social credit code is 91320113MA21DH7W5M (“Tsingsong Nanjing”); 

  

	6.	 Hangzhou Heda Biotech Investment Partnership (Limited
Partnership)(杭州和达生物医药创业投资合伙企业(有限合伙)), a limited partnership legally
established and existing in accordance with the PRC laws, whose unified social credit code is 91330101MA2AXNXM21 (“Heda Investment”); 

  

	7.	 Xiamen Ronghui Derong Equity Investment Partnership (Limited Partnership)
(厦门融汇德润股权投资合伙企业(有限合伙)), a limited partnership legally established and existing in
accordance with the PRC laws, whose unified social credit code is 91350211MA34071K50 (“Ronghui Derong”); 

  

	8.	 Ningbo Yanyuan Yaoshang Chanrong Equity Investment Partnership (Limited
Partnership)(宁波燕园姚商产融股权投资合伙企业(有限合伙)), a limited partnership legally
established and existing in accordance with the PRC laws, whose unified social credit code is 91330281MA2H6M3084 (“Yanyuan Chanrong”); 

  

	9.	 Ningbo Yanchuang Yaoshang Yangming Investment Partnership (Limited
Partnership)(宁波燕创姚商阳明创业投资合伙企业(有限合伙)), a limited partnership legally
established and existing in accordance with the PRC laws, whose unified social credit code is 91330281MA2H6M3084 (“Yanchuang Yangming”); 

  

	10.	 Jiangsu Yanyuan Dongfang Investment Partnership (Limited
Partnership)(江苏燕园东方创业投资合伙企业(有限合伙)), a limited partnership legally established and
existing in accordance with the PRC laws, whose unified social credit code is 91320300MA1UQURD8F (“Yanyuan Dongfang”); 

  
 - 1 - 

	11.	 Ningbo Rongshun Yanyuan Investment Partnership (Limited
Partnership)(宁波荣舜燕园投资合伙企业(有限合伙)), a limited partnership legally established and existing in accordance
with the PRC laws, whose unified social credit code is 91330201MA2AJPJ617 (“Rongshun Yanyuan”); 

  

	12.	 Ningbo Yanyuan Innovation Investment Partnership (Limited
Partnership)(宁波燕园创新创业投资合伙企业(有限合伙)), a limited partnership legally established and existing
in accordance with the PRC laws, whose unified social credit code is 91330201340622519X (“Yanyuan Innovation”); 

  

	13.	 Zhuzhou Guochuang Junyao Investment Partnership (Limited
Partnership)(株洲市国创君垚投资合伙企业(有限合伙)), a limited partnership legally established and existing in
accordance with the PRC laws, whose unified social credit code is 91430200MA4RGB014A (“Guochuang Junyao”); 

  

	14.	 Ningbo Hanhai Qianyuan Equity Investment Partnership (Limited
Partnership)(宁波瀚海乾元股权投资基金合伙企业(有限合伙)), a limited partnership legally
established and existing in accordance with the PRC laws, whose unified social credit code is 91330212MA2GW05H0A (“Hanhai Qianyuan”); 

  

	15.	 Hangzhou Haibang Yigu Investment Partnership (Limited
Partnership)(杭州海邦羿谷创业投资合伙企业(有限合伙)), a limited partnership legally established and existing
in accordance with the PRC laws, whose unified social credit code is 91330101MA2B02RD4R (“Haibang Yigu”); 

  

	16.	 Jialiang Shan, a Chinese citizen, whose ID number is [REDACTED]; 

 

	17.	 Zhejiang Silu Industry Investment Fund Partnership (Limited
Partnership)(浙江丝路产业投资基金合伙企业(有限合伙)), a limited partnership legally established and existing
in accordance with the PRC laws, whose unified social credit code is 91330101MA28WHW02L (“Silu Fund”); 

  

	18.	 Viva Biotech (Shanghai) Ltd.
(维亚生物科技(上海)有限公司), a limited company legally established and existing in accordance with the PRC laws, whose unified
social credit code is 91310115677881436W (“Viva Biotech”); 

  

	19.	 Tianjin Huatian Enterprise Management Consultation Limited Partner (Limited Partner)
(天津华天企业管理咨询合伙企业(有限合伙)), a limited partnership legally established and existing in accordance with the PRC
laws, whose unified social credit code is 91120118MA0727C0X0 (“Huatian Enterprise Management”; together with Fushi Capital, Tsingson Shenzhen, Tsingsong Nanjing, Heda Investment, Ronghui Derong, Yanyuan Chanrong, Yanhuang Yangming,
Yanyuan Dongfang, Rongshun Yanyuan, Yanyuan Innovation, Guochuang Junyao, Hanhai Qianyuan, Haibing Yigu, Jialiang Shan, Silu Fund and Viva Biotch, collectively referred to as the “Investors”); 

 

	20.	 Lili Qian, a Chinese citizen, whose ID number is [REDACTED]; 

  
 - 2 - 

	21.	 Zhengsong Zhang, a Chinese citizen, whose ID number is [REDACTED]; 

 

	22.	 Yunfei Zhang, a Chinese citizen, whose ID number is [REDACTED]; 

 

	23.	 Lihong Lou, a Chinese citizen, whose ID number is [REDACTED]; 

 

	24.	 Kai Zhou, a Chinese citizen, whose ID number is [REDACTED]; 

 

	25.	 Fang Yin, a Chinese citizen, whose ID number is [REDACTED] (together with Lili Qian, Zhengsong Zhang,
Yunfei Zhang, Lihong Lou and Kai Zhou, collectively referred to as the “Management”); 

  

	26.	 Hangzhou Yijing Biotech Partnership (Limited
Partnership)(杭州伊境生物科技合伙企业(有限合伙)), a limited partnership legally established and existing in accordance with the PRC
laws, whose unified social credit code is 91330100MA2HY0AEXX (“Management Holdco”); and 

  

	27.	 Hangzhou Lanjing Biotech Partnership (Limited
Partnership)(杭州阑境生物科技合伙企业(有限合伙)), a limited partnership legally established and existing in
accordance with the PRC laws, whose unified social credit code is 91330100MA2HY07T3Q (“ESOP Holdco”). 

 The above
parties are hereinafter collectively referred to as the “Parties”. When any party hereto is referred to as a “Party”, the other parties hereto will be referred to as the “Other Parties”. 

WHEREAS: 
  

	1.	 The Company is a limited liability company legally established and existing in accordance with PRC laws, which
was established on 26 June, 2019. The Company’s unified social credit code is 91330100MA2GNANB49, its current registered capital is US$30 million, and its business scope is: technology development, technology services, technology
consulting, and transfer of results: biotechnology, pharmaceutical technology (with respect to the above, except for the development and application of human stem cells, gene diagnosis and treatment technology); production: drugs; drugs,
pharmaceutical intermediates, Category I medical device wholesale and import and export business (except for those subject to special access control regulations stipulated by the state). 

 

	2.	 On September 15, 2020, the Parties entered into that certain Equity Transfer and Investment Agreement (the
“Investment Agreement”). According to the Investment Agreement, the Investors agree to collectively acquire 40% of the equity interest of the Company from I-Mab HK, corresponding to the unpaid
registered capital of the Company in the amount of US$12 million, and invest a total amount in RMB equivalent to US$120 million (collectively referred to as the “Investors Investment Amount”) to the Company after acquiring
such equity interest; the Management agree, through the Management Holdco, to acquire 10% of the equity interest of the Company from I-Mab HK, corresponding to the unpaid registered capital of the Company in
the amount of US$3 million, and invest a total amount in RMB equivalent to US$3 million to the Company after acquiring such equity interest; the ESOP Holdco agrees to acquire 5% of the equity interest of the Company from I-Mab HK, corresponding to the unpaid registered capital of the Company in the amount of US$1.5 million, which equity interest will be used to implement the Company’s employee equity incentive plan; I-Mab HK agrees to transfer to the Company the Pipeline Intangible Assets with a total valuation of US$105 million and pay to the Company US$30 million in cash, so as to complete its capital contribution
obligations with respect to the 45% remaining equity interest of the Company held by I-Mab HK (corresponding to registered capital of the Company in the amount of US$13.5 million). The aforementioned
transactions are referred to as the “Transactions”. Immediately after the completion of the Transactions, the Company’s shareholding structure is reflected in Schedule 1. 

  
 - 3 - 

 THEREFORE, in order to further stipulate the rights and obligations of the shareholders of the Company after
completion of the Transactions, the Parties have entered into the following agreement (unless otherwise provided in this Agreement, the terms used in this Agreement shall have the same meaning as that of the terms in the Investment Agreement): 

Article 1 Information and Inspection Rights 
  

	1.1	 Information and Inspection Rights. The Parties agree that, as long as an Investor holds
equity in the Company, the Investor or person designated by the Investor in writing shall have the right, to (a) inspect the assets and account capital flow records, financial statements, financial books, financial documents and other related
documents of the Company and its Subsidiaries during the Company’s normal office hours, or (b) communicate with directors, supervisor(s), officers, key employees, employees of the Company, and professional service organisations engaged by
the Company such as auditors and legal consultants on affairs of the Company; in each case, provided that notice is delivered to the Company five (5) Working Days in advance. At the same time, the Company shall provide the Investors with the
following information with respect to the Company and its Subsidiaries: 

  

	 	(1)	 Within twenty-one (21) days after the end of each fiscal month,
provide Investors with unaudited monthly financial statements; 

  

	 	(2)	 Within one hundred and twenty (120) days after the end of each fiscal year, provide Investors with annual
financial statements and annual audit report audited by an auditor acceptable to the Investors Directors; 

  

	 	(3)	 Within thirty (30) days before the commencement of each fiscal year, provide Investors with the financial
budget for such fiscal year; 

  

	 	(4)	 Provide copies of documents and other materials given to any other shareholders; 

 

	 	(5)	 Other information and materials reasonably requested by the Investors. 

The aforesaid financial statements shall be prepared in accordance with China’s generally accepted accounting principles, and shall
include balance sheets, profit and loss statements, and cash flow statements. All of the aforesaid audits must be conducted in accordance with China’s generally accepted accounting principles by an auditor acceptable to the Investors Directors.

  

	1.2	 Termination. The above-mentioned information and inspection right will terminate upon
completion of the Qualified IPO (as defined in the Investment Agreement). 

  
 - 4 - 

 Article 2 Equity Lockup 

 

	2.1	 I-Mab HK, the Management, Management Holdco and ESOP Holdco
hereby agree that before the Qualified IPO of the Company and as long as the Investors still hold equity in the Company, without consent of the Majority Investors (as defined in the Investment Agreement) and consent of the Investors who have the
rights to appoint Investor Directors, none of I-Mab HK, the Management, Management Holdco and ESOP Holdco shall dispose of any equity of the Company directly or indirectly held by them through transfer, gift,
pledge or otherwise, or create any incumbrance on such equity in favour of any third party. However, (i) I-Mab HK may transfer equities in the Company to its Affiliated Company(ies) (as defined in the
Investment Agreement), provided that such equity transfer shall not affect I-Mab HK’s obligations hereunder; for the avoidance of doubt, in such case, the equity transfer shall not take effect unless and
until the relevant Affiliated Company(ies) of I-Mab HK have agreed to assume all covenants, representations, obligations and responsibilities which are owed by I-Mab HK
to the Investors hereunder; (ii) in case of joinder of new Management members (the list of Management members to join after the Closing Date has been disclosed in Schedule 2 attached hereto), the existing Management members may transfer equity
to the new Management members as listed in Schedule 2; for the avoidance of doubt, in such case, the equity transfer between Management members shall not take effect unless and until the new Management member(s) have agreed to subject themselves to
the provisions of this Article 2.1 and have executed relevant joinder agreement; and (iii) for purposes of implementing the ESOP or other incentive arrangement that may be approved by the Investor Directors, the grantee(s) of incentives may be
granted option or may accept transfer of equity; and (iv) any member of the Management may exercise the repurchase rights in accordance with Article 2.2 (the foregoing are collectively referred to as the “Exempt Transfer”). The
Exempt Transfer shall not be subject to the Company’s or other shareholders’ consent, right of first refusal, right of co-sale or similar rights. 

 

	2.2	 The Parties hereby acknowledge and agree that the Share of Equity held by each member of Management
through the Management Holdco shall be restricted equity. After a member of the Management pays in an instalment of capital contribution for his/her Share of Equity in accordance with the provisions of Article 4.3(8) of the Investment Agreement,
such paid-in portion of Share of Equity shall be vested one (1) year from the relevant paid-in date (however, if the date on which such member of the Management
paid in the relevant instalment is earlier than the due date of such instalment as provided in Article 4.3(8) of the Investment Agreement, the relevant portion of Share of Equity shall be vested one (1) year from such due date instead) (for the
avoidance of doubt, the Share of Equity, after being vested, shall still be subject to the provisions of Article 2.1 hereof), till all portion of the Share of Equity is vested. However, upon a successful Qualified IPO of the Company or occurrence of
a Deemed Liquidation Event, then all unvested Share of Equity held by the Management shall be immediately and fully vested. If, before the Share of Equity held by a member of Management is fully vested, (a) such member of the Management departs
for any reason, or (b) the Board of Directors has determined that there is a material violation of labour contract, or non-compete and intellectual property assignment agreement by such member of
Management, or material failure to perform his/her duties, or other material fault of such member of the Management, and therefore resolves to forfeit his/her Share of Equity, then other members of Management shall have the pro rata rights to
purchase all Share of Equity directly or indirectly held by such member of Management who departed or committed a material fault, which pro rata rights are in proportion to the Share of Equity then held by the relevant members of Management. The
purchase price shall be calculated based on the amount actually paid by the selling member of Management plus interest accrued at an annualised simple interest of 5%. Upon occurrence of aforesaid termination of employment or material fault of any
Management member before his/her Share of Equity is fully vested, if the other Management members fail to exercise their repurchase rights or fail to fully exercise their pro rata repurchase rights in proportion to their respective Share of Equity,
then QIAN Lili and ZHANG Zhengsong shall be responsible for repurchasing Share of Equity of the said Management member that are not repurchased. For the avoidance of doubt, in such case, the other shareholders of the Company do not have any right of
first refusal, co-sale right or any other similar rights with respect to such purchase. 

  
 - 5 - 

	2.3	 The Parties hereby acknowledge and agree that any equity held by the ESOP Holdco in the Company shall
only be used for grant of equity incentives under equity incentive plan in accordance with the decision of the Board of Directors, and unless for the purpose of implementing the equity incentive plan and approved by resolution of the Board of
Directors, the ESOP Holdco shall not directly or indirectly transfer, pledge, create incumbrance or otherwise dispose of any equity held by it in the Company. 

Article 3 Investors’ Preferred Rights 
  

	3.1	 Pre-emptive Rights. 

 

	 	(1)	 From the Closing Date of the Transactions and prior to the Qualified IPO of the Company, if the Company intends
to increase its registered capital or issue new shares in any form, arrangement shall be made in accordance with provisions of this Agreement and the Company’s articles of association, and the Investors shall have the right to subscribe for the
Company’s new registered capital or new shares at the same price and conditions up to a percentage of such new registered capital or new shares equal to its then shareholding percentage in the Company (“First Round Pre-emptive Rights”). If any Investor gives up exercise of its First Round Pre-emptive Rights in whole or in part, then Investors who have fully exercised the First
Round Pre-emptive Rights shall have the right to subscribe for the part of the new registered capital or new shares of the Company against which the other Investors had the right to exercise their pre-emptive rights but have gave up exercise of such rights, up to a percentage which is equal to the proportion of the equity of the Company held by it to the total equity of the Company held by all Investors who
have fully exercised the First Round Pre-emptive Rights (“Second Round Pre-emptive Rights”; together with the First Round
Pre-emptive Rights, the “Pre-emptive Rights”). 

  

	 	(2)	 If the Company intends to increase registered capital or issues new shares in any form, the Company shall serve
a written notice (“Capital Increase Notice”) to all Investors at least fifteen (15) Working Days in advance. The Capital Increase Notice shall include the price and conditions of the plan to increase registered capital or issue
new shares (including the amount/number of new registered capital/shares), and at the same time, issue an offer to invite Investors to subscribe for the Company’s new registered capital or new shares at such price and conditions.

  
 - 6 - 

	 	(3)	 An Investor shall notify the Company in writing within ten (10) Working Days after receipt of the above
offer (the “First Participation Period”) whether to exercise its First Round Pre-emptive Rights. If the Investor decides to exercise its Pre-emptive
Rights, a written commitment to exercise the Pre-emptive Rights shall also be made, in which the amount to be exercised shall be indicated. 

 

	 	(4)	 If after expiration of the First Participation Period, any Investor fails to exercise or does not fully
exercise its First Round Pre-emptive Rights, the Company shall promptly notify the Investors who have fully exercised their First Round Pre-emptive Rights, and each
Investor who has fully exercised its First Round Pre-emptive Rights shall have the right to send a written notice to the Company within five (5) Working Days after receipt of such notice of the Company
(the “Second Participation Period”), and, based on the proportion of its equity in the Company to equity of the Company held by all Investors who have fully exercised their First Round
Pre-emptive Rights, has the pro rata priority rights over other shareholders of the Company and third parties to subscribe for the part of Company’s proposed new registered capital or new shares against
that the other Investors may exercise the First Round Participation Rights but have gave up exercise of such rights. 

  

	 	(5)	 Within ninety (90) Working Days after the expiration date of the First Participation Period or the Second
Participation Period (if applicable, as the case may be), the Company may enter into a corresponding capital increase contract or similar agreement for the remaining part of the proposed new registered capital or proposed new shares which are not
subject to the above-mentioned Pre-emptive Rights or against which no Pre-emptive Rights are exercised; provided, however, such capital increase contract or similar
agreement cannot stipulate terms and conditions that are more favourable than those stated in the Capital Increase Notice. If the Company fails to enter into a capital increase contract or a similar agreement within ninety (90) Working Days,
then the remaining part of the above-mentioned new registered capital or new shares shall again be subject to the Pre-emptive Rights in accordance with the provisions of this Article 3.1.

  

	 	(6)	 This Article 3.1 does not apply to any capital increase for purposes of implementation of employee equity
incentive plans or other incentive plan approved by the Investors Directors, capital increase for purposes of adjustments under Article 3.6, nor capital increase allocated to all shareholders on a pro rata basis for realisation of profits or for
converting capital reserve to registered capital as approved by resolution of the Shareholders. 

  
 - 7 - 

	3.2	 Right of First Refusal. 

 

	 	(1)	 Subject to the provisions of Article 2 of this Agreement, if any shareholder of the Company (the
“Selling Shareholder”) wishes to transfer any equity of the Company directly or indirectly held by it (the “Offered Equity”) to any third party (the “Proposed Transferee”), the Selling Shareholder
shall issue a written notice to the Company and the Investors (the “Transfer Notice”), indicating its transfer intention, transfer price and conditions, and identity of the Proposed Transferee. The Investors (except for the investor
who is a Selling Shareholder) have the right of first refusal to purchase all or part of the Offered Equity at the same price and conditions, in proportion to the amount of equity then held by them in the Company (the “Right of First
Refusal”). The Investors have the right to, within ten (10) Working Days after receiving the Transfer Notice (the “First RoFR Exercise Period”), respond in writing to the Company and the Selling Shareholder requesting
to exercise the Right of First Refusal. If the Investors have responded in writing requesting to exercise the Right of First Refusal within the First RoFR Exercise Period, such Investors have the right to purchase all or part of the Offered Equity
at the same price and conditions with priority over other shareholders of the Company other than the Investors and any third parties. If any Investor fails to exercise or does not fully exercise its Right of First Refusal, then the Investors who
have fully exercised their Right of First Refusal have the right to purchase the remaining Offered Equity against which no Right of First Refusal of Investors is exercised or Investors fail to fully exercise the Right of First Refusal, in proportion
to the amount of equity then held by them in the Company; such Investors shall have five (5) days after expiration of the First RoFR Exercise Period (the “Second RoFR Exercise Period”) to decide whether to exercise such further
Right of First Refusal. 

  

	 	(2)	 Within ninety (90) Working Days after the expiration of the First RoFR Exercise Period or the Second RoFR
Exercise Period (if applicable, as the case may be), the Selling Shareholder may enter into a corresponding equity transfer contract for the remaining part (if any) of the Offered Equity which is not subject to the above-mentioned Right of First
Refusal or against which no Right of First Refusal is exercised; provide, however, the equity transfer contract cannot stipulate terms and conditions that are more favourable than the prices and conditions stated in the Transfer Notice. If the
Selling Shareholder fails to enter into an equity transfer contract within the above-mentioned ninety (90) Working Days’ period, then the remaining part of the above-mentioned Offered Equity shall again be subject to the Right of First
Refusal under this Article 3.2. 

  

	 	(3)	 For the avoidance of any doubt, the Parties confirm that transfer equity held by any Investor in the Company to
its Affiliates is not subject to the Company’s or other shareholders’ consent, right of first refusal, right of co-sale or similar rights. Without the prior written consent of I-Mab HK, each shareholder shall not, and shall cause its respective Affiliates not to, directly or indirectly transfer all or any part of equity of the Company to any person who directly competes with the
Company’s principal business (i.e., early stage discovery, development and commercialization of innovative biological drugs in the field of tumour immunology and autoimmune diseases) (the “Competitors of the Company”; the
number of Competitors of the Company shall be not greater than 20). The initial list of the Competitors of the Company is set forth in Schedule 3 hereto, which list may be updated by approval of the Board (including consent of both Investor
Directors). 

  

	 	(4)	 This Article 3.2 does not apply to any Exempt Transfer listed in Article 2.1, the repurchase under Article 3.5,
or implementation of the compensation measures described in Article 3.6. 

  
 - 8 - 

	3.3	 Co-Sale Right. 

 

	 	(1)	 Subject to Article 2.1 hereof, when I-Mab HK (including any Affiliate
of I-Mab HK who acquires equity of the Company through Exempt Transfer pursuant to Article 2.1(i) hereof) and/or any Management member and/or the Management Holdco and/or the ESOP Holdco propose to transfer
any equity of the Company held by them, if any Investor decides not to exercise the Right of First Refusal specified in Article 3.2 of this Agreement, such Investor shall have the right to, within five (5) Working Days after expiration of the
First RoFR Exercise Period, respond in writing to the Company and I-Mab HK and/or any Management member and/or the Management Holdco and/or the ESOP Holdco (as the Selling Shareholder(s)) requesting to
participate in the sale of equity of the Company by such Selling Shareholder(s) under the same conditions of sale (the “Co-Sale Rights”). Except for the situation described in Article 3.3(2),
the amount of equity that any Investor who intends to exercise the Co-Sale Rights by participating in the sale shall not exceed the product of the following: (i) the quantity of the Offered Equity,
multiplied by (ii) a fraction, the numerator of which is the amount of equity of the Company held by the Investor who intends to exercise the Co-Sale Rights, the denominator of which is the total number
of equity of the Company held by all Investors who intend to exercise the Co-Sale Rights and the amount of equity of the Company held by the said Selling Shareholder(s) at that time. The said Selling
Shareholder(s) shall procure the Proposed Transferee to agree to the above-mentioned co-sale by the Investors; if the Proposed Transferee does not agree to the above-mentioned
co-sale, the said Selling Shareholder(s) shall not transfer Offered Equity to the Proposed Transferee unless prior written consent of the Investors who intend to exercise the
Co-Sale Rights is obtained or the said Selling Shareholder(s) agree to purchase the equity to be sold by the Investors who intend to exercise the Co-Sale Rights at the
same price and conditions. 

  

	 	(2)	 Subject to other terms of this Agreement, when I-Mab HK (including any
Affiliate of I-Mab HK who acquires equity of the Company through Exempt Transfer pursuant to Article 2.1(i) hereof) and/or the Management and/or the Management Holdco and/or the ESOP Holdco have already
cumulatively sold equity held by them in the Company in excess of 6% of the then total registered capital of the Company, and I-Mab HK and/or the Management and/or the Management Holdco and/or the ESOP Holdco
wish to further sell equity directly or indirectly held by them in the Company to any Proposed Transferee, and any Investor decides not to exercise its Right of First Refusal as specified in Article 3.2 of this agreement, then such Investor has the
right to, within five (5) Working Days after expiration of the First RoFR Exercise Period, respond in writing to the Company and I-Mab HK and/or the Management and/or the Management Holdco and/or the ESOP
Holdco (as the Selling Shareholder(s)), requesting to sell any part or all equity of the Company held by it to the Proposed Transferee under the same conditions of sale (the “Full Co-Sale
Rights”). If the Proposed Transferee does not agree to purchase any part or all equity that any Investor requests to sell by exercising the Fully Co-Sale Rights,
I-Mab HK and/or the Management and/or the Management Holdco and/or the ESOP Holdco (as the Selling Shareholder(s)) shall purchase all equity requested to be sold by the Investors who intend to exercise the
Full Co-Sale Rights at the same conditions, otherwise they shall not transfer Offered Equity to the Proposed Transferee. 

 

	 	(3)	 This Article 3.3 does not apply to any Exempt Transfer listed in Article 2.1, the repurchase under Article 3.5,
or implementation of the compensation measures described in Article 3.6. 

  
 - 9 - 

	3.4	 Liquidation Preference. 

Before the Qualified IPO of the Company, in the event of the Company’s liquidation, dissolution, termination of the Company’s
principal business, or occurrence of a Deemed Liquidation Event (as defined below), the Company’s property shall be used to pay off liquidation expenses, employee salaries and social insurance expenses, statutory compensation, taxes owed by the
Company and the Company debts in the order prescribed by law. If there is any remaining property after the Company’s liquidation property is liquidated in accordance with the above mentioned provisions, or in case of a Deemed Liquidation Event,
the Company or all shareholders have surplus after deduction of relevant taxes (collectively referred to as the “Remaining Property”), the Remaining Property shall be allocated in the following order: 

 

	 	(1)	 An Investor has the right to take precedence over other shareholders of the Company to receive the higher of
(“Liquidation Preference Amount”): (i) x) the Investors Investment Amount paid by the Investor, plus y) investment return accrued from the date on which the Investor actually paid the relevant Investors Investment Amount until the
payment date of the relevant Liquidation Preference Amount, calculated on the basis of the annualised 10% simple interest rate on the Investor Investment Amount so paid, plus z) the Company’s undistributed profits (if any) corresponding to the
Investor’s equity; or (ii) among the Remaining Property, the part that the Investor would be entitled to receive base on its shareholding percentage in the Company. If the Remaining Property is insufficient to pay all Investors their
Liquidation Preference Amount in full, the Company shall allocate the Remaining Property among the Investors in proportion of each Investor’s Liquidation Preference Amount. The aforesaid Liquidation Preference Amount shall be paid to the
Investors by RMB cash. 

  

	 	(2)	 If there is any assets remaining after the Investors’ Liquidation Preference Amount has been paid in full,
the remaining assets shall be distributed ratably among the other shareholders of the Company according to the relative proportion of equity held by them in the Company. 

 

	 	(3)	 Each Party shall take all effective measures in compliance with the applicable PRC laws to ensure that the
Investors obtain their priority proceeds from the distributable Remaining Property in the above-mentioned order, in a manner consistent with applicable PRC laws. I-Mab HK shall complete procedures that are
required under the applicable laws for performance of obligations under this Article 3.4. 

  

	 	(4)	 For the purposes of this Agreement, “Deemed Liquidation Events” shall mean (i) all or
substantially all of the Company’s assets, business or equity are sold, transferred or otherwise disposed of in a transaction or series of related transactions ; or (ii) all or substantially all of the Company’s intellectual property
rights are transferred or exclusively licensed to third parties for use in a transaction or series of related transactions; or (iii) more than fifty percent (50%) of the Company’s equity is sold, transferred or otherwise disposed of in a
transaction or series of related transactions, or due to the merger, reorganisation, business integration, or any other form of transaction between the Company and other entities, resulting in shareholders of the Company that accounted for fifty
percent (50%) or more of the voting rights before such transactions no longer hold fifty percent (50%) or more of the Company’s voting rights after such mergers, reorganisations, business integration, or any other form of transaction, or due to
any of the above transactions, I-Mab HK (with its Affiliates) is no longer the Company’s single largest shareholder, or (iv) any shareholder (with its Affiliates) of the Company holds or exceeds
fifty percent (50%) of equity in the Company in a transaction or series of related transactions. 

  
 - 10 - 

	3.5	 Repurchase 

 

	 	(1)	 If the Company fails to close a Qualified IPO within four (4) years after the Closing Date of the
Transactions, then within three (3) years after the expiration of such four (4) year period, or other period that may then be agreed between I-Mab and the Investors through consultation, any Investor
will have the right to elect to request I-Mab HK to repurchase all or any part of the equity held by such Investor in the Company by cash. The unit repurchase price of the corresponding equity represented by
per 1 U.S. dollar of registered capital of the Company shall be (a) the Investor’s Original Unit Investment Price (as defined below; or if the Original Unit Investment Price has been adjusted in accordance with Article 3.6, the Adjusted
Unit Investment Price shall be applied instead), plus (b) accrued from the date that the Investor actually paid the relevant Investors Investment Amount till the date when the repurchase price is paid, interest calculated at the annualised 10%
simple interest rate on the Original Unit Investment Price (or the Adjust Unit Investment Price), plus (c) the Company’s undistributed profits (if any) corresponding to such equity (collectively referred to as the “Repurchase
Price”). The total Repurchase Price that an Investor is entitled to shall be a product obtained by multiplying the unit Repurchase Price of per 1 U.S. dollar of registered capital calculated pursuant to the preceding provisions, by the
total amount of registered capital corresponding to equity of the Company which the Investor requests to be repurchased. 

  

	 	(2)	 I-Mab HK and the Investors hereby agree that if any Investor intends to
exercise the Repurchase Right in accordance with the provisions of Article 3.5(1) above, subject to the approval procedures of I-Mab 天境生物 (NASDAQ: IMAB; hereinafter referred to as
“I-Mab”) and the then applicable U.S. securities laws and regulatory rules on public companies, if it is then intended to have I-Mab to use its stock as
consideration to repurchase the equity of the Company against which the Investor intends to exercise the Repurchase Right (hereinafter referred to as “Repurchase by Stock”), the relevant repurchase agreement shall be negotiated
separately by the Investors and I-Mab. If the value of I-Mab stock obtained by an Investor through Repurchase by Stock has reached an amount equal to the product
obtained by multiplying the unit Purchase Price under Article 3.5(1) by the quantity of equity held by such Investor, I-Mab HK shall no longer bear the repurchase obligations under this Article 3.5 with
respect to such equity of the Company held by the Investor. From expiration of the four (4) years period after the Closing Date and within three (3) years thereafter, or within exercising period that may be otherwise agreed between I-Mab HK and the Investors through consultation, with consent of the Majority Investors, negotiation may be initiated with I-Mab on
I-Mab’s repurchase of equity of the Company held by the Investors by issuance of I-Mab stock as consideration. 

  
 - 11 - 

	 	(3)	 I-Mab HK and Company shall complete procedures that are required under
the applicable laws for performance of obligations under this Article 3.5. I-Mab HK guarantees that, within 1 year from the date on which any Investor delivers request of repurchase to the Company in writing,
the Investor will receive Repurchase Price for all equity with respect to which it has exercised right of repurchase. Before I-Mab HK has paid the Investors the Repurchase Price in full, the Investors shall
still be entitled to the full shareholder rights under the laws of the PRC and this Agreement for the equity in which it has not obtained relevant portion of Repurchase Price. If I-Mab HK disposes of all or
substantially all of the equity directly or indirectly held by it in I-Mab Bio-Tech (Tianjin) Co., Ltd. and I-Mab Biopharma
(Shanghai) Co., Ltd. and such disposal of equity may impact I-Mab HK’s capability to perform its repurchase obligations under this Article 3.5, I-Mab HK shall cause
other company(ies) within the Group who have capacity of repurchase to jointly covenant to perform the repurchase obligations, so as to make up for deficiency in the Warrantor’s capacity of repurchase. 

 

	 	(4)	 The Repurchase Price shall be adjusted according to stock split, dividend distribution, capital reorganisation
and other similar situations. 

  

	3.6	 Anti-Dilution 

If, after the Closing Date and before the Company’s Qualified IPO, the Company issues new registered capital (or securities that can be
converted into or can be exercised as the Company’s equity) with a unit price of per 1 U.S. dollar of registered capital (the “New Unit Price”) that is lower than any Investor’s Original Unit Investment Price at its
investment in the Company in the Transactions, the Investor will have the right to require the Original Unit Investment Price of its equity held in the Company to be reduced to an amount that is equal to the New Unit Price (the Original Unit
Investment Price, after such adjustment, shall be referred to as the “Adjusted Unit Investment Price”), and recalculate the amount of equity in the Company that it should have been entitled to obtain based on its Adjusted Unit
Investment Price. After the recalculation, the amount of Company registered capital held by such Investor shall be equal to the quotient obtained by dividing the Investors Investment Amount paid by such Investor in the Transactions, by the Adjusted
Unit Investment Price (“Equity after Adjustment”). The difference between the Investor’s Equity after Adjustment and the Investor’s then actual equity shall, to the extent permitted by the applicable laws, be compensated
(i) by the Company by issuing additional registered capital to the Investor at the lowest price permitted by law, or (ii) by I-Mab HK by transferring equity of the Company to the Investor at the
lowest price permitted by law. For the avoidance of doubt, the “Original Unit Investment Price” of the equity held by each Investor is initially RMB equivalent to US$10 per US$1 of registered capital (calculated according to the USD
to RMB central parity rate announced by the People’s Bank of China on the day of such Investor’s payment of its Investors Investment Amount). However, equity/shares issuance for implementation of employee equity incentive plans or other
incentive arrangements approved by the Investors Directors shall not trigger the adjustments under this Article 3.6. For the avoidance of doubt, if, in accordance with Shareholders’ resolution, the Company uses capital reserve fund to increase
the registered capital of all shareholders on a pro rata basis, the Original Unit Investment Price of the anti-dilution right investor under this Article shall be diluted and reduced proportionally. 

  
 - 12 - 

	3.7	 Most Favoured Nation. In the event any Investor is entitled to, with respect to its
investment in these Transactions, any terms that are more favourable than other Investors except terms under the applicable laws and regulations or under the Transaction Documents (as defined in the Investment Agreement) (the “More
Favourable Terms”), the other Investors shall, with respect to their investment in these Transaction, automatically be entitled to the same More Favourable Terms. 

 

	3.8	 Effect of Preferred Rights. The foregoing special rights of Investors as stipulated in
Article 3 of this Agreement shall automatically lapse at the time as necessary for initial public offering of the Company and in accordance with requirements of the regulatory authority for initial public offering; provided, however, such rights
shall be automatically reinstated as if such rights had never expired or terminated, when (i) the Company withdraws the application for initial public offering, (ii) the Company fails to successfully complete the issuance with eighteen
(18) months after submission of application for initial public offering (this period can be extended by the Parties through written agreement before the expiration), or (iii) the relevant regulatory authority overrules or rejects the
Company’s application for Qualified IPO (based on the earliest occurrence of the preceding three events). 

  

	3.9	 New Shareholders. If, after execution of this Agreement, any shareholder of the Company
intends to transfer all of the equity held by it in the Company to any third party, the transferee of the equity shall sign an agreement with the Parties to this Agreement simultaneously with the transfer of the equity, stipulating that the
transferee shall be assigned rights and obligations of the transferring shareholder. If, after execution of this Agreement, any shareholder of the Company intends to transfer a part of the equity held by it in the Company to any third party, the
transferee of the equity shall sign an agreement with the Parties to this Agreement simultaneously with the transfer of the equity, stipulating that the transferee and the transferor shall respectively be entitled to the rights of the transferor
hereunder immediately prior to the transfer, and be subject to the obligations of the transferor hereunder immediately prior to the transfer, with respect to equity of the Company respectively held by each of them. Rights and obligations of the
transferee(s) of equity shall be subject to agreement among the transferee(s) and all shareholders of the Company at that time. 

Article 4 Corporate Governance 
  

	4.1	 Composition of Board. The Company shall establish a Board of Directors. As of the Closing
Date, the Board of Directors shall consist of seven (7) persons, of which: I-Mab HK has the right to appoint three (3) directors; Fushi Capital has the right to appoint one (1) director;
Tsingsong Shenzhen and Nanjing Tsingsong have the right to appoint one (1) director jointly (together with the director appointed by Fushi Capital, collectively referred to as the “Investors Directors”); the Management Holdco
has the right to appoint one (1) director; I-Mab HK also has the right to nominate one (1) independent director. The Company shall have a Chairman of the Board, who shall be appointed by I-Mab HK. Each Shareholder of the Company shall exert affirmative votes on election of the aforesaid nominees of Director s, so as to ensure persons nominated by the Parties who are entitled to appoint Directors
pursuant to this Article 4.1 be elected as Directors of the Company. The Company shall have the right to appoint observers to the Board. Each Board observer shall be entitled to: (i) simultaneously with the Directors of the Company, receive all
notices for Board meetings, meeting materials and other documents that the Company delivers to the Directors; (ii) attend Board meetings and make speech, and receive copies of Board resolutions and meeting minutes, provided that the observer
shall have no voting rights on any matter reviewed by the Board; and (ii) customary information rights of Directors. 

  
 - 13 - 

	4.2	 Shareholders’ Power. The Shareholders shall exercise the following powers to:

  

	 	(1)	 Decide the Company’s business policy and investment plan; 

 

	 	(2)	 Elect and replace directors, and decide on matters related to the remuneration of directors;

  

	 	(3)	 Elect and replace supervisors who are representatives of the Shareholders, and determine matters related to the
remuneration of supervisors; 

  

	 	(4)	 Review and approve the report of the Board of Directors; 

 

	 	(5)	 Review and approve the report of the supervisors; 

 

	 	(6)	 Review and approve the Company’s annual financial budget plan and final account plan;

  

	 	(7)	 Review and approve the Company’s profit distribution plan and loss
make-up plan; 

  

	 	(8)	 Adopt resolutions on issuance of corporate bonds; 

 

	 	(9)	 Adopt resolutions on the Company’s public offering of shares, determination or amendment of the
Company’s IPO plan (including without limitation jurisdiction of IPO); 

  

	 	(10)	 Adopt resolutions on shareholders’ transfer of equity interest or change of shareholding structure of the
Company (provided that in the event any Party transfers equity in compliance with this Agreement, the other Parties shall cooperate to pass the relevant Shareholders resolutions); 

 

	 	(11)	 Adopt resolutions on the increase or decrease of the registered capital of the Company or its Subsidiaries;

  

	 	(12)	 Adopt resolutions on matters of the Company or its Subsidiaries such as mergers, divisions, changes in
organisational form, dissolution, termination, liquidation, ceasing to operate principal business of the Company, or Deemed Liquidation Events; 

  

	 	(13)	 Amend the Company’s or its Subsidiaries’ articles of association. 

In shareholders meetings, the shareholders shall exercise their voting power in accordance with the proportion of registered capital
respectively subscribed by them. When the shareholders adopt resolutions on items (9)-(13) above, such resolutions must be passed by shareholders representing more than two-thirds (2/3) of the voting power
(including the consent of the Majority Investors (as defined in the Investment Agreement; for the avoidance of doubt, shall include consent of the Investors who are entitled to appoint Directors)). Except for the above mentioned circumstances, the
resolution of the shareholders shall be passed by shareholders representing more than one-half (1/2) of the voting power. 

  
 - 14 - 

	4.3	 Board of Directors’ Power. The Board of Directors shall exercise the following power
to: 

  

	 	(1)	 Decide the business plan and investment plan of the Company and its Subsidiaries; 

 

	 	(2)	 Formulate the annual financial budget plan and final account plan of the Company and its Subsidiaries;

  

	 	(3)	 Formulate profit distribution plan and loss make-up plan of the Company
and its Subsidiaries; 

  

	 	(4)	 Formulate plans for the Company and/or its Subsidiaries to increase or decrease the registered capital;

  

	 	(5)	 Approve, implement or amend the Company’s employee equity incentive plan and specific plans thereof;

  

	 	(6)	 Formulate merger, division, change of company organisation form, and dissolution plan of the Company and/or its
Subsidiaries; 

  

	 	(7)	 Approve, extend or amend related party transactions or agreements between the Company and/or its Subsidiaries
and any of its shareholders, directors and officers or their respective Affiliates (except related party transactions or agreements necessary for the Exempt Transfer described in Article 2.1 hereof, or execution, extension or amendment of any
related party transaction or agreement to the extent such execution, extension or amendment is made in accordance with related party transaction / agreement framework plan approved in advance by the Board of Directors (including the Investors
Directors); 

  

	 	(8)	 Approve the Company and/or its Subsidiaries to sell, mortgage, pledge, transfer or dispose of the intellectual
property related to the Pipelines as contributed by I-Mab HK to the Company in the Transaction, or sale or disposal of all or substantially all of assets related to any Target Pipeline of the Company;

  

	 	(9)	 Any commercial cooperation between the Company or its Subsidiaries and any third party regarding the
intellectual property related to the Pipelines as contributed by I-Mab HK to the Company in the Transaction, including but not limited to joint development, external licensing, etc.; 

 

	 	(10)	 Company’s or its Subsidiaries’ provision of securities to third parties; 

 

	 	(11)	 Amendment of the list of the Competitors of the Company as attached to this Agreement; 

  
 - 15 - 

	 	(12)	 The Company’s obtainment of license from any third party under any Intellectual Property, or the license
of any Intellectual Property of the Company to any third party, or change of any existing license agreement or arrangement in connection with any Target Pipeline (as defined in the Investment Agreement); 

 

	 	(13)	 Decide on the establishment of the internal management organisation of the Company and its Subsidiaries;

  

	 	(14)	 Formulate the Company’s basic management policies (including without limitation policies on the
Company’s provision of securities or lending of loans to third parties, borrowing of loans, related party transactions); and 

  

	 	(15)	 Other powers granted under the applicable laws, the Company’s articles of association, or by the
Shareholders. 

  

	4.4	 Each member of the Board of Directors shall have one vote. The quorum for meetings of Board of Directors
shall exceed two-thirds (2/3) of the total number of directors, and the Board of Directors resolutions reached are valid only if with affirmative votes of a majority of the directors. Notwithstanding the
foregoing, the Board of Directors shall not adopt resolutions on the matters listed in item (5) above without the affirmative votes of over two-thirds (2/3) of the directors, including affirmative votes
of at least one Investor Director; and the Board of Directors shall not adopt resolutions on the mattes listed in items (6) to (12) above without the affirmative votes of a majority of the directors, including affirmative votes of both
Investors Directors. 

 Article 5 Act in Concert 

 

	5.1	 I-Mab HK, Management Holdco and ESOP Holdco agree that, unless
otherwise agreed to among such three Parties, as long as each of Management Holdco and ESOP Holdco respectively holds equity in the Company, each of Management Holdco and ESOP Holdco irrevocably agrees to, when exercising the following rights as a
shareholder of the Company, act in concert with I-Mab HK and follow I-Mab’s instruction: 

 

	 	(1)	 the right to convene, hold and attend Shareholders’ meetings; 

 

	 	(2)	 the right to make proposals as a Shareholder; 

 

	 	(3)	 the right to exercise voting rights on the matters which, according to the laws and regulations, the
Company’s articles of association, and provisions of this Agreement, shall be reviewed by Shareholders (except the matters set forth in Article 4.2(9) hereof). 

 

	5.2	 I-Mab HK and Management Holdco agree that, unless otherwise
agreed to between such two Parties, as long as Management Holdco holds equity in the Company, Management Holdco irrevocably agrees to cause any Director appointed by it to, when exercising the following rights as a director of the Company, act in
concert with majority of the directors appointed by I-Mab HK and follow the instruction of majority of the directors appointed by I-Mab HK: 

 

	 	(1)	 The right to convene, hold and attend Board meetings; 

  
 - 16 - 

	 	(2)	 The right to make proposals as a director; 

 

	 	(3)	 The right to exercise voting rights on the matters which, according to the laws and regulations, the
Company’s articles of association, and provisions of this Agreement, shall be reviewed by the Board of Directors. 

  

	5.3	 Except the shareholders’ rights subject to the foregoing commitment to act in concert, the
provisions of this Article 5 shall not affect other rights of I-Mab HK, Management Holdco and ESOP Holdco that they are entitled to under the laws and regulations, the Company’s articles of association
and provisions of this Agreement as shareholders, including without limitation information rights, dividend rights, economic rights, etc.. 

Article 6 Liability for Breach of Contract; Indemnification 
  

	6.1	 If any Party to this Agreement breaches the provisions of this Agreement, the Other Parties shall have
the right to claim indemnification for the losses suffered by them as a result of the breach in addition to other rights that they may be entitled to under this Agreement. 

 

	6.2	 Subject to other provisions of this Agreement, a Party to this Agreement (hereinafter referred to as the
“Indemnifying Party”) shall indemnify and hold harmless the Other Parties (hereinafter referred to as the “Indemnified Parties”) against losses or payment incurred in connection with any of the following
circumstances: (a) any representation or statement made by the Indemnifying Party in this Agreement is false, untrue or misleading, (b) the Indemnifying Party has violated or failed to fully fulfil the covenants, warranties or obligations
under this Agreement, in each case except the circumstances which have been waived by the Other Parties in writing. The Indemnifying Party shall indemnify the Indemnified Parties against any and all losses directly or indirectly suffered by the
Indemnified Parties as a result of the foregoing circumstances. 

  

	6.3	 If any Party to this Agreement breaches the provisions of this Agreement, in addition to any other
rights under this Agreement, the Other Parties shall have the right to require the breaching Party to specifically and completely perform the obligations under this Agreement. 

 

	6.4	 Notwithstanding anything to the contrary herein, the provisions of this Article shall survive
termination of the Parties’ rights and obligations hereunder, and survive the termination of this Agreement. 

Article 7 Effectiveness, Amendment and Termination of the Agreement 

 

	7.1	 Effectiveness. This Agreement shall take effect on the Closing Date, subject to the due
execution of this Agreement by the Parties or their authorised representatives (Chinese non-natural persons must also affix their official seals). 

 

	7.2	 Amendment. Any amendment or alteration to this Agreement shall be negotiated by all
Parties, and shall be effective only after a written contract on such amendments or alteration have been signed by the Parties. 

  

	7.3	 Termination. This Agreement may be terminated prior to expiration under any of the
following circumstances: 

  
 - 17 - 

	 	(1)	 With the unanimous written consent of all Parties; 

 

	 	(2)	 Any Party breaches this Agreement and does not cue the breach within thirty days (30), or the breach have
occurred for twice or more cumulatively, then the non-breaching Parties shall have the right to unilaterally terminate this Agreement; 

 

	 	(3)	 If force majeure occurs and as a result the fundamental purpose of this Agreement cannot be achieved, any Party
may terminate this Agreement. 

  

	7.4	 Effect of Termination. When this Agreement is terminated in accordance with Article 7.3,
except the provisions in Article 5 (Liability for Breach of Contract; Indemnification), Article 8 (Miscellaneous) and this Article 7.4, this Agreement shall be invalid and shall no longer be binding or effective, and the Parties will be no longer
required to bear the responsibilities and obligations under this Agreement; provided, however, despite termination of this Agreement, a Party shall still be liable for any losses incurred by the Other Parties as a result of its breach of this
Agreement before the termination. 

 Article 8 Miscellaneous 

 

	8.1	 Notice. 

 

	 	(1)	 All notices, claims, requests, consents, waivers and other communications required or permitted under this
Agreement shall be in writing (including telegram, fax or similar written form) and shall be sent, delivered or mailed, e-mailed or faxed to the following addresses: 

 

					
	 Company:
	  	 I-Mab Biopharma (Hangzhou) Co., Ltd.

 

	  	 Attention:
  
	  	[REDACTED]
	  	 Phone:
  
	  	[REDACTED]
	  	 Fax:
  

E-mail:
  
	  	[REDACTED]
	  	Address:	  	[REDACTED]
		
	 I-Mab HK:
	  	 I-MAB BIOPHARMA HONGKONG LIMITED

 

	  	 Attention:
  
	  	[REDACTED]
	  	 Phone:
  
	  	[REDACTED]
	  	 Fax:
  

E-mail:
	  	[REDACTED]
	  	  
 Address:
	  	[REDACTED]

  
 - 18 - 

					
	 Investors:
	  	 Hangzhou Fushi Investment Management Partnership (Limited Partnership)

 

		  	 Attention:
  
	  	 [REDACTED]
  

	  	 Phone:
  
	  	 [REDACTED]
  

	  	 Fax:
  

E-mail:
  
	  	[REDACTED]
	  	Address:	  	[REDACTED]
		
		  	 Shenzhen Tsingsong Shengrui Investment Partnership (Limited Partnership)

 

			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	 Fax:
  

E-mail:
	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Nanjing Tsingsong Healthcare Investment Partnership (Limited Partnership)
			
		  	Recipient:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	Fax:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Hangzhou Heda Biotech Investment Partnership (Limited Partnership)
			
		  	Recipient:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	Fax:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]

  
 - 19 - 

					
		  	Xiamen Ronghui Derong Equity Investment Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	Fax:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Ningbo Yanyuan Yaoshang Chanrong Equity Investment Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	Fax:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Ningbo Yanchuang Yaoshang Yangming Investment Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	Fax:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]
		
		  	Jiangsu Yanyuan Dongfang Investment Partnership (Limited Partnership)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	Fax:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
			
		  	Address:	  	[REDACTED]

  
 - 20 - 

					
		  	 Ningbo Rongshun Yanyuan Investment Partnership (Limited Partnership)

 

		  	 Attention: [REDACTED]
  

		  	 Phone: [REDACTED]
  

		  	 Fax: [REDACTED]
  

		  	 E-mail: [REDACTED]

 

		  	 Address: [REDACTED]
  

		  	 Zhuzhou Guochuang Junyao Investment Partnership (Limited Partnership)

 

		  	 Attention: [REDACTED]
  

		  	 Phone: [REDACTED]
  

		  	 Fax: [REDACTED]
  

		  	 E-mail: [REDACTED]

 

		  	 Address: [REDACTED]
  

		  	 Ningbo Hanhai Qianyuan Equity Investment Partnership (Limited Partnership)

 

		  	 Attention: [REDACTED]
  

		  	 Phone: [REDACTED]
  

		  	 Fax: [REDACTED]
  

		  	 E-mail: [REDACTED]

 

		  	 Address: [REDACTED]
  

		  	 Hangzhou Haibang Yigu Investment Partnership (Limited Partnership)/Jialiang Shan

 

		  	 Attention: [REDACTED]
  

		  	Phone: [REDACTED]
		
		  	Fax: [REDACTED]
		
		  	 E-mail: [REDACTED]

 

		  	Address: [REDACTED]

  
 - 21 - 

					
		  	Zhejiang Silu Industry Investment Fund Partnership (Limited Partnership)
		
		  	Attention: [REDACTED]
		
		  	Phone: [REDACTED]
		
		  	Fax: [REDACTED]
		
		  	E-mail: [REDACTED]
		
		  	Address: [REDACTED]
		
		  	Viva Biotech (Shanghai) Ltd.
		
		  	Attention: [REDACTED]
		
		  	Phone: [REDACTED]
		
		  	Fax: [REDACTED]
		
		  	E-mail: [REDACTED]
		
		  	Address: [REDACTED]
		
		  	Tianjin Huatian Enterprise Management Consultation Limited Partner (Limited Partner)
			
		  	Attention:	  	[REDACTED]
			
		  	Phone:	  	[REDACTED]
			
		  	Fax:	  	[REDACTED]
			
		  	E-mail:	  	[REDACTED]
		  	  
 Address:
	  	  
 [REDACTED]

		
	 Management / Management Holdco:
	  	
	  	 Attention:
  
	  	[REDACTED]
	  	 Phone:
  
	  	[REDACTED]
	  	 Fax:
  

E-mail:
  
	  	[REDACTED]
	  	Address:	  	[REDACTED]

  
 - 22 - 

					
	 ESOP Holdco:
	  		  	
	  	 Attention:
  
	  	 [REDACTED]
  

	  	 Phone:
  
	  	 [REDACTED]
  

	  	 Fax:
  
	  	 [REDACTED]
  

		  	 E-mail:
  
	  	 [REDACTED]
  

		  	Address:	  	[REDACTED]

  

	 	(2)	 Each notice, request or other communication delivered or served in accordance with the provisions of Article
8.1(1) shall be deemed as delivered or served as follows: (a) if sent by a courier company or personally delivered, it shall be deemed as delivered when the relevant notice, request or communication is sent to the above-mentioned address;
(b) if sent by fax, then the relevant notice, request or communication shall be deemed as delivered when it is transmitted to the above fax number and the report of successful fax transmission is obtained; (c) if sent by e-mail, it shall be deemed as delivered twenty-four hours after the date on which the e-mail containing the relevant notice, request or communication as recorded by the
sender’s computer is sent, provide, however, if the sender does not receive the recipient’s confirmation of receipt of the above e-mail within twenty-four hours (except for automatic email
confirmation of receipt), the above notice, request or other communication shall be sent by courier or fax by the end of the same day. 

  

	8.2	 Governing law. This Agreement shall be governed by and be construed in accordance with the
PRC laws. 

  

	8.3	 Dispute Resolution. In the event of is a dispute over the interpretation or performance of
this Agreement, the Parties shall firstly attempt to resolve the dispute through friendly consultation. If the dispute cannot be resolved through consultation within thirty (30) days after one Party delivers written notice to the Other Parties
requesting the commencement of consultation, then any Party may submit the dispute to the China International Economic and Trade Arbitration Commission for arbitration, and the arbitration shall be conducted in Hangzhou according to the said
commission’s arbitration rules then in force. The arbitration award shall be final and binding on all Parties and cannot be appealed. The arbitration costs shall be borne by the losing party unless the arbitration award provides otherwise. When
any dispute occurs and when any dispute is under arbitration, except the matter under disputes, the Parties shall continue to exercise their other rights and perform their other obligations under this Agreement. 

 

	8.4	 Confidentiality. Each of the Parties shall not, and shall cause its respective Affiliates,
shareholders, directors, officers, employees, representatives or agents not to, directly or indirectly disclose the existence of this Agreement or any information related to the Transactions (including any information obtained by the Party during
the course of the negotiation and execution of this Agreement), unless (a) it has obtained the prior written consent of the non-disclosing Parties, or (b) such information is required to be disclosed
by the applicable laws and is only disclosed to the extent necessary to comply with the applicable laws or any regulations or policies of any stock exchange, provided, however that the disclosing Party shall, within a reasonable time before the
disclosure or submission of the relevant information, seek opinions of the Other Parties on such disclosure and submission, and that if required by the Other Parties, the disclosing Party shall seek for confidential treatment of the disclosed or
submitted information to the extent possible. Notwithstanding the foregoing, I-Mab, being a company listed in the United States, shall have the right to disclose the Company’s financing information in
accordance with the requirements of U.S. securities laws without the need for separately obtaining the Parties’ consent. After the Closing, each of the Company, I-Mab HK and the Investors shall have the
right to disclose the existence of the Investors’ investment in the Company to third parties or the public; provided, however, the Investors shall seek the opinions of I-Mab HK when disclosing information
related to the Company’s investment matters, with a view to comply with the information disclosure requirements under the U.S. securities laws. 

  
 - 23 - 

	8.5	 Severability. The obligations under this Agreement shall be regarded as separate
obligations and be independently enforceable. When one or more obligations of this Agreement are unenforceable, the enforceability of other obligations shall not be affected. If this Agreement is not enforceable against any Party, the enforceability
of this Agreement among the Other Parties shall not be affected. If one or more of the provisions of this Agreement are found to be invalid, illegal or unenforceable in any respect according to any applicable law, or a government agency requests
amendment of one or more provisions of this Agreement, the validity, legality and enforceability of the remaining provisions shall not be affected or damaged in any way. The Parties shall endeavour to replace these invalid, illegal or unenforceable
provisions with valid provisions through sincere consultations, and the economic effects of such valid provisions shall be as similar as possible to those of the invalid, illegal or unenforceable provisions. 

 

	8.6	 Entire Agreement. This Agreement (including the other Transaction Documents and any other
documents referred to or contemplated hereunder or thereunder) constitutes the entire agreement among the Parties with regard to the subjects hereof, and supersedes any other agreements or intentions previously reached by the Parties on the same
subjects. 

  

	8.7	 Assignment. Without prejudice to the provisions of the PRC laws and the other provisions
of this Agreement, the Investors have the right to assign their rights and obligations under this Agreement to their respective Affiliates, and such assignment does not require prior consent of Other Parties or the Company. An Investor has the right
to assign its rights and obligations under this Agreement to any third party along with the sale or transfer (if any) of its equity in the Company to such third party; provided, however, such equity transfer shall be subject to the other
Investors’ Right of First Refusal under Article 3.2 hereof. Notwithstanding anything to the contrary herein, after completion of its capital contribution obligation, any Investor may transfer its then effective rights and obligations under the
Agreement to its Affiliates along with the sale or transfer (if any) of its equity in the Company, which transfer or assignment shall not be subject to any other shareholders’ consent, right of first refusal, right of co-sale or similar rights. Except the foregoing, without the prior written consent of each other Party, no Party shall assign its rights or obligations under this Agreement; any assignment without the Other
Parties’ consent shall be invalid. 

  
 - 24 - 

	8.8	 Counterparts. This Agreement is written in Chinese. This Agreement shall be signed in
thirty (30) original copies. Each Party shall hold one (1) original copy, and the remaining original copies shall be held by the company. Each copy of this Agreement shall be equally effective. 

 

	8.9	 Priority. If, in order to request any government agency to carry out any specific act,
separate agreements in connection with the Transactions (including but not limited to, equity transfer agreement, the Company’s articles of association or amendments to the articles of association, as may be amended from time to time) have to
be signed in accordance with the standard templates or requirements of the government agency, this Agreement shall control over any such agreements, and such agreements shall only be used to request the government agency to implement the specific
act, and shall not be used to establish or as an evidence of any rights or obligations of the relevant parties on matters that may be stipulated in such agreements. 

(No text below) 
  

  
 - 25 - 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
  

	
	Company:
	
	I-Mab Biopharma (Hangzhou) Co., Ltd.
	(Seal)
	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
  

	
	I-Mab HK:
	
	I-MAB BIOPHARMA HONGKONG LIMITED
	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Hangzhou Fushi Investment Management Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Shenzhen Tsingsong Shengrui Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Nanjing Tsingsong Healthcare Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Hangzhou Heda Biotech Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Xiamen Ronghui Derong Equity Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

  
 Signature Page to
Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Ningbo Yanyuan Yaoshang Chanrong Equity Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Ningbo Yanchuang Yaoshang Yangming Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Jiangsu Yanyuan Dongfang Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Ningbo Rongshun Yanyuan Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Ningbo Yanyuan Innovation Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Zhuzhou Guochuang Junyao Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Hangzhou Haibang Yigu Investment Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Jialiang Shan 
 (Seal) 

 

	
	 /s/ Jialiang Shan

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Zhejiang Silu Industry Investment Fund Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Viva Biotech (Shanghai) Ltd. 
 (Seal) 

 

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Investors: 

Tianjin Huatian Enterprise Management Consultation Limited Partner (Limited Partner) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Management: 

Lili Qian 
  

	
	 /s/ Lili Qian

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Management: 

Zhengsong Zhang 
  

	
	 /s/ Zhengsong Zhang

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Management: 

Yunfei Zhang 
  

	
	 /s/ Yunfei Zhang

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Management: 

Lihong Lou 
  

	
	 /s/ Lihong Lou

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Management: 

Kai Zhou 
  

	
	 /s/ Kai Zhou

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Management: 

Fang Yin 
  

	
	 /s/ Fang Yin

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Hangzhou Yijing Biotech Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 IN WITNESS WHEREOF, the Parties have caused their respective authorized representatives to execute this
Agreement on the date first above written. 
 Hangzhou Lanjing Biotech Partnership (Limited Partnership) 

(Seal) 
  

	
	 /s/ Authorized Signatory

	Name: Authorized Signatory
	Position:

 Signature Page to Shareholders Agreement 

 Schedule 1 Shareholding Structure Immediately After Completion of the Transactions

 Schedule 1 

 Schedule 2 List of Management Members to Join After the Closing Date 

Schedule 2 

 Schedule 3 List of Competitors of the Company 

Schedule 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]